

Wi-Fi Login Instructions
Inside Front Cover

2016

Gastrointestinal Cancers Symposium

INSIGHT ON NOVEL MECHANISMS AND PRECISION CARE

January 21-23, 2016

Moscone West Building • San Francisco, California

gicasym.org • #GI16

PROGRAM

COSPONSORED BY





Stay Connected at the Symposium

Find a Colleague

Use the Find a Colleague directory, accessible through the Attendee Resource Center (gicasym.org/arc), to search for attendees and send a direct, private message to connect while onsite. New this year—you can search the directory by cosponsor.

Complimentary Wi-Fi

NETWORK: GI2016
No password required.

The Wi-Fi network does not support video streaming or the downloading of large files.

Ask Questions via eQ&A

Electronic Question and Answer (eQ&A) will be available in the General Sessions and Oral Abstract Sessions. Submit questions online at any time.

Participate in Sessions with ARS

Play an active role in case-based panel discussions by using audience response system (ARS) technology.

eQ&A and ARS instructions can be found on page 10.

2016 Gastrointestinal Cancers Symposium

CONTENTS

Committees	2
Continuing Medical Education and Symposium Feedback	4
Policies	8
Attendee Resources	10
Ancillary Educational Event	12
Program at a Glance	13
Program by Day	17
Poster Sessions Directory	36

SAVE THE DATE:

2017 Gastrointestinal Cancers Symposium

January 19-21, 2017

Moscone West Building • San Francisco, California

Committees

Steering Committee

Cathy Eng, MD, FACP—Chair

The University of Texas MD Anderson Cancer Center

Mitchell C. Posner, MD—Immediate Past Chair

The University of Chicago Medical Center

Laura Dawson, MD

Princess Margaret Cancer Centre

William Grady, MD

Fred Hutchinson Cancer Research Center

Nipun B. Merchant, MD, FACS

University of Miami Medical Center

Program Committee

George A. Fisher, MD, PhD—Chair

Stanford University School of Medicine

Bertram Wiedenmann, MD, PhD—Chair-Elect

Charité University Hospital, Berlin

Amitabh Chak, MD

University Hospitals Case Medical Center

Andrew T. Chan, MD, MPH

Massachusetts General Hospital

Prajnan Das, MD, MS, MPH

The University of Texas MD Anderson Cancer Center

Jorge Gallardo, MD

Centro Oncología Clínica Alemana

Karyn A. Goodman, MD, MS

University of Colorado School of Medicine

Steven N. Hochwald, MD

Roswell Park Cancer Institute

Rodrigo Jover, MD, PhD

Alicante General University Hospital

Yuko Kitagawa, MD, PhD, FACS

Keio University School of Medicine

Vincent J. Picozzi, MD, MMM

Virginia Mason Medical Center

Diane L. Reidy, MD

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

Ulysses Ribeiro, MD, PhD

University of São Paulo

Manish A. Shah, MD

Weill Cornell Medical College

Vincenzo Valentini, MD, Professor

Università Cattolica S. Cuore

Sharon Weber, MD

University of Wisconsin—Madison

Special thanks to our Content Advisors from the American Association for the Study of Liver Disease and the Society of Thoracic Surgeons

Tushar Patel, MBChB

Mayo Clinic

Boris Blechacz, MD, PhD

The University of Texas MD Anderson Cancer Center

Michael J. Weyant, MD

University of Colorado Hospital

Michael Kent, MD

Harvard Medical School

News Planning Team

William Grady, MD

*Fred Hutchinson Cancer Research Center,
University of Washington School of Medicine*
Representing American Gastroenterological
Association Institute

Karyn A. Goodman, MD, MS

University of Colorado School of Medicine
Representing American Society for Radiation
Oncology

Smitha S. Krishnamurthi, MD

*Seidman Cancer Center, University Hospitals
Case Medical Center*
Representing American Society of Clinical
Oncology

Jennifer F. Tseng, MD, MPH

*Beth Israel Deaconess Medical Center;
Harvard Medical School*
Representing Society of Surgical Oncology

Continuing Medical Education and Symposium Feedback

Overview

Multidisciplinary in content and scope, the 2016 Gastrointestinal Cancers Symposium brings together a diverse group of stakeholders involved in the prevention, detection, and treatment of gastrointestinal (GI) cancers. The meeting's intimate and interactive setting facilitates a forum for networking and discussion to exchange ideas, best practices, and science that will lead to future progress. General Sessions and Oral Abstract Sessions engage attendees through eQ&A, allowing attendees to propose questions online at any time. Daily Keynote Lecture Sessions highlight the most up-to-date science and clinical practice for the various disease sites.

Educational Need Statement

The Gastrointestinal Cancers Symposium provides a distinct opportunity for clinicians across disciplines and professions to keep pace with rapidly evolving evidence to guide the best care for patients diagnosed with these diseases. Although the incidence of and mortality from these diseases continues to be significant, emerging science is offering potential options for treatment, particularly in immunotherapy, that represent a new direction for clinicians. This creates an ongoing educational need to enable a proper consideration of these options against a prior standard of care.

Target Audience

This Symposium is designed for physicians and researchers interested in the prevention, screening, evaluation, and management of gastrointestinal cancers, including, but not limited to, medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists.

This Symposium may also be of benefit to nurses, pharmacists, physician assistants, and other health care professionals involved in clinical care and research in this area.

Learning Objectives

Upon participation in this activity, attendees will be able to

- Select appropriate screening and diagnostic procedures to optimize treatment plans for patients with gastrointestinal cancers;
- Compare and contrast multidisciplinary approaches for diagnosis and management of patients with gastrointestinal cancer from different regions of the world;
- Apply new data on drug development and clinical trials that may impact treatment for patients with gastrointestinal cancers; and
- Utilize biomarkers, big data, and population science approaches to individualize care plans for patients with gastrointestinal cancers.

This activity was planned in the context of the following attributes:

INSTITUTE OF MEDICINE COMPETENCIES

- Delivering Patient-Centered Care
- Practicing Evidence-Based Medicine
- Focusing on Quality Improvement

ACCREDITATION COUNCIL FOR GRADUATE MEDICAL EDUCATION CORE COMPETENCIES

- Patient Care
- Medical Knowledge
- Practice-Based Learning and Improvement
- Systems-Based Practice

Accreditation and CME Credit Designation

The American Society of Clinical Oncology (ASCO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The live activity has been approved for a maximum of 25.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer and Unlabeled Usage Statement can be found online at gicasym.org.

Symposium Feedback and Certificates

Every participant is encouraged to submit a Symposium Feedback Form, provide session ratings, and access certificates for the Symposium through the iPlanner app, available for download via the Attendee Resource Center (gicasym.org/arc). Your feedback is utilized by leadership to enhance programs, develop new initiatives, gauge educational impact, and plan for future symposia.

Feedback and CME credit requests are due by February 25, 2016.

Access the following via the iPlanner mobile app:

- To provide feedback on a specific session
 1. Select a session by searching by time or track
 2. Select "Rate This Session" to submit feedback on each session you attend
- To access certificates and claim CME credit
 1. Select a session by searching by time or track
 2. Select "Claim CME Credit" to obtain a CME Certificate or Certificate of Participation
- To access the Symposium Feedback Form
 1. Choose "Give Feedback" from the iPlanner home page to submit a Symposium Feedback Form

CERTIFICATE OF ATTENDANCE

Attendees can download a Certificate of Attendance from the Attendee Resource Center if they need a record of their attendance at the Symposium but do not require documentation for continuing education purposes. Please note that this certificate does not award any *AMA PRA Category 1 Credit™*.

CERTIFICATE OF PARTICIPATION

All nonphysician attendees are welcome to submit a request for a Certificate of Participation through the iPlanner. Please note, however, that all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.

For questions or assistance, contact cme@asco.org.

Conflict of Interest Disclosure

As the CME provider for the Symposium, ASCO is committed to balance, objectivity, and scientific rigor in the management of financial interactions with for-profit health care companies that could create real or perceived conflicts of interest. Participants in the Symposium have disclosed their financial relationships in accordance with ASCO's Policy for Relationships with Companies; review the policy at asco.org/rwc.

ASCO offers a comprehensive disclosure management system, using one disclosure for all ASCO activities. Members and participants in activities use coi.asco.org to disclose all interactions with companies. Their disclosure is kept on file and can be confirmed or updated with each new activity.

Please email coi@asco.org with specific questions or concerns.

Policies

If you have any questions regarding these policies or attendee conduct, please contact the staff at the Symposium Registration and Customer Service Desk in the Level 1 Lobby or meetings@asco.org.

SPECIAL ASSISTANCE

The Symposium Cosponsors, the Moscone West Building, and all official Symposium hotels comply with the Americans with Disabilities Act. If you require special assistance onsite, please contact the staff at the Symposium Registration and Customer Service Desk in the Level 1 Lobby or meetings@asco.org.

AGE REQUIREMENTS FOR ATTENDEES

Because of the detailed nature of the programs and forums, no one under the age of 18 will be admitted to any official Symposium function. This includes, but is not limited to, all Symposium sessions, the Posters, Exhibits, and Food Service Room, and all evening events offered by the Symposium Cosponsors.

IMPORTANT SECURITY AND ATTENDEE CONDUCT INFORMATION

For security reasons, the 2016 Gastrointestinal Cancers Symposium badge will be required for admittance to all events. Please wear your badge so that it can be easily seen at all times. Lost badges should be reported to the Registration staff immediately. The following badge policies will be in effect throughout the Symposium:

- The 2016 Gastrointestinal Cancers Symposium badge is the sole property of the Symposium Cosponsors.
- The badge is nontransferable.
- False certification of individuals as paid Symposium attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any Symposium event, or any inappropriate or unauthorized conduct will be just cause for repossessing badges of any individuals involved and expelling all parties involved from the Symposium without obligation on the part of the Symposium Cosponsors for refund of any fees.

In addition, individuals who are part of the 2016 Gastrointestinal Cancers Symposium may not engage in any demonstrations or other behavior that the Symposium Cosponsors deems to be potentially disruptive to the conduct of the Symposium. Violation of this rule is grounds for immediate dismissal from the Symposium and/or ineligibility for attendance at future ASCO symposia or meetings. Any person who is dismissed from the Symposium may request that the Symposium Cosponsors review the matter, provided, however, that such dismissal will be effective immediately and will continue until and unless the Symposium Cosponsors issue a contrary decision.

CANCELLATION STATEMENT

The Symposium Cosponsors reserve the right to cancel 2016 Gastrointestinal Cancers Symposium because of unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to each registrant.

EQUAL OPPORTUNITY STATEMENT

The 2016 Gastrointestinal Cancers Symposium is available without regard to race, color, sex, national origin, disability, age, or veteran status as provided by law and in accordance with the Symposium Cosponsors' respect for personal dignity.

AUTHORIZATION FOR USE OF IMAGE, NAME, AND OTHER LIKENESS

By attending the 2016 Gastrointestinal Cancers Symposium or entering in the facility in which the 2016 Gastrointestinal Cancers Symposium takes place, you agree that ASCO or authorized third parties may photograph or record your likeness, image, name, voice, and/or words, and may publish, display, reproduce, copy, and distribute your likeness, image, name, voice, and/or words for promotional, educational, or membership activities worldwide in all forms of media now known or later developed, including but not limited to advertising, training, websites, presentations, and marketing materials. You further acknowledge that ASCO or authorized third parties shall have the right, but not the obligation, to identify you in connection with such media by name and/or affiliation.

RECORDING (AUDIO, VIDEO, AND STILL PHOTOGRAPHY)

Copyright of the 2016 Gastrointestinal Cancers Symposium program is owned by ASCO. ASCO reserves the rights to all recordings or reproductions of presentations at this Symposium and all ASCO meetings and symposia. Any photography, filming, taping, recording, or reproduction in any medium, including via the use of tripod-based equipment, of any of the programs presented at the 2016 Gastrointestinal Cancers Symposium without the express written consent of ASCO is strictly forbidden. Exception: Non-flash photography and audio or video recording using hand-held equipment, for strictly personal, social, or noncommercial use, are permitted if not disruptive, as determined by ASCO.

NO SOLICITING IN THE EXHIBITS ROOM

The exhibits give the 2016 Gastrointestinal Cancers Symposium attendees the opportunity to meet with representatives from the health care industry about their products and services in a professional atmosphere that is consistent with the educational mission of the Symposium. Symposium attendees are prohibited from soliciting business from other attendees or exhibitors in the Exhibits Room, unless the solicitation occurs within the specific exhibit space of the attendee.

NO SMOKING

Smoking is prohibited in all the 2016 Gastrointestinal Cancers Symposium facilities, including public areas and the Posters, Exhibits, and Food Service Room. This policy will be enforced.

2016 Gastrointestinal Cancers Symposium Cosponsors

American Gastrointestinal Association Institute
American Society of Clinical Oncology
American Society for Radiation Oncology
Society of Surgical Oncology

Attendee Resources

For Wi-Fi login instructions, see the inside front cover.

eQ&A

Attendees can submit questions during the General Sessions and Oral Abstract Sessions using eQ&A online. The session rooms will also be equipped with microphones for attendees who wish to ask questions orally.

1. Connect to the Internet using the free Symposium Wi-Fi.
2. In your web browser, go to pollev.com/GI16. The screen will update automatically when eQ&A is open.
3. Type the speaker's name and your question into the dialogue box, and select "Submit Response".



ARS Sessions

Use ARS technology to weigh in and compare your treatment decisions to those of your colleagues. Connect to ARS at the beginning of ARS-enabled sessions to ensure you join the discussion.


1. Connect to the Internet using the complimentary Symposium Wi-Fi.
2. In your Web browser, go to pollev.com/GI16. The screen will update automatically when the presenter displays a poll.
3. Select your response.

iPlanner

The iPlanner keeps you connected to the Symposium activities:

- ▶ Interact with speakers during sessions via eQ&A and ARS.
- ▶ Claim CME credit and provide real-time feedback during sessions.
- ▶ Keep up with the latest meeting news via *Daily News* and Twitter.

The iPlanner is available for smartphones and tablets—download from your device's app store now by searching for "Symposia iPlanner".



Session Slides

Attendees can view session slides via the Virtual Meeting at gicasym.org/arc. Slides will be available no later than 12 hours after the presentation time.

Attendee Resource Center

The Attendee Resource Center (gicasym.org/arc) is an all-in-one location for links to publications and planning tools. Log in with your badge number or ASCO.org username and password to access the following:

- ▶ Abstracts
- ▶ Find a Colleague directory to search for attendees and send private messages
- ▶ Presentations and slides via Virtual Meeting, along with the related mobile app, ASCO iMeeting
- ▶ *Daily News*
- ▶ Symposium Feedback Form, CME Request, and Certificate of Attendance
- ▶ Exhibitor listing and floor plan



Exhibits

The Symposium Cosponsors encourage all attendees to visit the exhibits in the West Hall on Level 1 on Thursday and Friday from 7:00 AM to 7:00 PM. The exhibits offer you an opportunity to extend your learning about the most advanced therapies, products, and services in the treatment of gastrointestinal cancers. Visit gicasym.org to view a list of exhibiting companies.

Career Opportunities Board

New this year, explore career opportunities or post an open position at your organization on the Career Opportunities Board located in the Posters, Exhibits, and Food Service Room on Level 1. All postings must be approved by Symposium staff. If you are interested in posting a job, visit the staff at the Registration and Customer Service Desk in the Level 1 Lobby.

Prayer and Meditation Room

A nondenominational Prayer and Meditation Room is available for attendees. Located in Room 3005 on the 3rd floor, the room is open on Thursday from 7:00 AM to 7:00 PM, Friday from 6:30 AM to 7:00 PM, and Saturday from 6:30 AM to 5:30 PM.

Ancillary Educational Event

The event listed below is an independent, accredited educational activity held adjunct to the 2016 Gastrointestinal Cancers Symposium. Presentations are not sponsored or endorsed by any of the cosponsoring organizations of the Symposium.

Title: Promising Progress: Improving Knowledge and Emerging Treatments in Advanced Pancreatic Cancer

Date and Time: Thursday, January 21, 2016, from 7:15 PM to 8:45 PM (*registration and dinner provided from 6:45 PM to 7:15 PM*)

Location: San Francisco Marriott Marquis, Yerba Buena Ballroom, Salon 7

CME Provider and Supporter(s): This event is organized and accredited by MediCom Worldwide, Inc. and is supported by educational grants provided by Celgene Corporation.

Registration and Contact Information: To learn more about the event, please contact Arielle Fera at afera@medicaled.com.

EVENT SUMMARY

This accredited activity will provide attendees with critical information concerning new and emerging therapies for pancreatic cancer, thereby supporting treatment choices that incorporate the newest, most appropriate, and effective therapies for the individual patient. By emphasizing the importance of a patient-centered approach to treatment as well as shared decision making in all patients, including those with advanced pancreatic cancer whose options may be severely limited, Symposium attendees will be encouraged to educate their patients about this disease and its potential therapeutic options and strategies. As a result, Symposium attendees will succeed in engaging the patient in treatment and supporting increased quality of life. MediCom will also collect information concerning participants' approaches to therapy in pancreatic cancer and their expectations as to how future developments may impact treatment paradigms for this disease.

FACULTY

James L. Abbruzzese, MD, FACP—Chair
Duke University

Andrew H. Ko, MD
UCSF Helen Diller Family Comprehensive Cancer Center

Philip Agop Philip, MD, PhD, FRCP
Karmanos Cancer Institute

Program at a Glance

Thursday, January 21

7:00 AM-7:00 PM	Exhibits Open
7:00 AM-7:45 AM	Complimentary Continental Breakfast
7:45 AM-9:30 AM	WELCOME AND GENERAL SESSION 1: How We Should Be Screening and Novel Screening Techniques
9:30 AM-10:00 AM	Break
10:00 AM-11:00 AM	KEYNOTE LECTURES: Microbial Pathogens and Malignancy
11:00 AM-12:30 PM	GENERAL SESSION 2: Is There an Optimal Chemotherapy Regimen for Advanced Gastric Cancer? (ARS)
12:30 PM-2:00 PM	POSTER SESSION A: Cancers of the Esophagus and Stomach <i>With complimentary boxed lunch</i>
	TRIALS IN PROGRESS POSTER SESSION A: Cancers of the Esophagus and Stomach <i>With complimentary boxed lunch</i>
12:45 PM-1:45 PM	 FELLOWS, RESIDENTS, AND JUNIOR FACULTY NETWORKING LUNCHEON
2:00 PM-3:30 PM	ORAL ABSTRACT SESSION: Cancers of the Esophagus and Stomach
3:30 PM-4:00 PM	Break
4:00 PM-5:30 PM	GENERAL SESSION 3: Multimodal Approaches for Advanced Gastroesophageal Junction Cancers—Challenging Cases from the United States and Europe versus Asia (ARS)
5:30 PM-7:00 PM	POSTER SESSION A: Cancers of the Esophagus and Stomach (Continued) and Networking Reception <i>With complimentary wine and cheese</i>
	TRIALS IN PROGRESS POSTER SESSION A: Cancers of the Esophagus and Stomach (Continued) and Networking Reception <i>With complimentary wine and cheese</i>
5:45 PM-6:45 PM	POSTER WALKS
6:00 PM-7:00 PM	BREAKOUT SESSION: Mechanical Palliation in Advanced Gastroesophageal Cancer
	BREAKOUT SESSION: Rare Tumors of the Upper GI Tract



COMPLIMENTARY TICKETED SESSION: Space will be held for attendees with tickets until the start of the session. At the session start time, attendees without tickets will be admitted if there is space available, and attendees with tickets will no longer be guaranteed participation in the session. Attendance is limited to Fellows, Residents, and Junior Faculty.

6:30 AM-7:55 AM	Complimentary Continental Breakfast
7:00 AM-7:00 PM	Exhibits Open
6:55 AM-7:55 AM	BREAKOUT SESSION: Fighting Cancer With Big Data—Using Population Data to Improve Outcomes
	BREAKOUT SESSION: Recent Advances in the Treatment of Neuroendocrine Tumors
7:55 AM-9:30 AM	WELCOME AND GENERAL SESSION 4: Innovative Approaches to Hepatopancreatobiliary Disease (ARS)
9:30 AM-10:00 AM	Break
10:00 AM-11:00 AM	KEYNOTE LECTURE: Inflammatory Networks and Cancer Immune Surveillance
11:00 AM-12:30 PM	GENERAL SESSION 5: Pancreatic Cancer—An International Dialogue About Patterns of Care and Their Impact on Outcomes
12:30 PM-2:00 PM	POSTER SESSION B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract <i>With complimentary boxed lunch</i>
	TRIALS IN PROGRESS POSTER SESSION B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract <i>With complimentary boxed lunch</i>
12:45 PM-1:45 PM	POSTER WALKS
2:00 PM-3:30 PM	ORAL ABSTRACT SESSION: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
3:30 PM-4:00 PM	Break
4:00 PM-5:30 PM	GENERAL SESSION 6: Hepatocellular Carcinoma Tumor Board (ARS)
5:30 PM-7:00 PM	POSTER SESSION B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract (Continued) and Networking Reception <i>With complimentary wine and cheese</i>
	TRIALS IN PROGRESS POSTER SESSION B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract (Continued) and Networking Reception <i>With complimentary wine and cheese</i>
6:00 PM-7:00 PM	BREAKOUT SESSION: Perspectives on Physician Aid in Dying (ARS)

6:30 AM-5:30 PM	Food Service Room Open
6:30 AM-7:55 AM	Complimentary Continental Breakfast
6:55 AM-7:55 AM	BREAKOUT SESSION: Multiplex Approach to Colon Cancer Testing—Is It Ready for Prime Time?
	BREAKOUT SESSION: The Importance of Recognizing Microsatellite Instability Tumors—Cancer Prevention and New Options for Treatment
7:00 AM-7:55 AM	POSTER SESSION C: Cancers of the Colon, Rectum, and Anus
	TRIALS IN PROGRESS POSTER SESSION C: Cancers of the Colon, Rectum, and Anus
7:55 AM-9:30 AM	WELCOME AND GENERAL SESSION 7: Controversies in Screening and Surveillance in Colorectal Cancer
9:30 AM-10:00 AM	Break
10:00 AM-11:00 AM	KEYNOTE LECTURES: Global Overview of Colorectal Cancer—Past, Present, and Future
11:00 AM-12:30 PM	GENERAL SESSION 8: Diverse International Perspectives on the Work-up and Management of Rectal Cancer
12:30 PM-2:00 PM	POSTER SESSION C: Cancers of the Colon, Rectum, and Anus (Continued) <i>With complimentary boxed lunch</i>
	TRIALS IN PROGRESS POSTER SESSION C: Cancers of the Colon, Rectum, and Anus (Continued) <i>With complimentary boxed lunch</i>
12:45 PM-1:45 PM	POSTER WALKS
2:00 PM-3:30 PM	ORAL ABSTRACT SESSION: Cancers of the Colon, Rectum, and Anus
3:30 PM-4:00 PM	Break
4:00 PM-5:30 PM	GENERAL SESSION 9: Difficult Cases in Rectal Cancer (ARS)

NEED SUPPLIES?

Find water stations, note pads, and pens at the entrance to the General Session Room.

NEED TO CHARGE A DEVICE?

Power strips for charging your devices are located on each row in the General Session Room and on select networking rounds in the Posters, Exhibits, and Food Service Room.

Thursday, January 21

7:00 AM–7:00 PM

Exhibits Open

LEVEL 1, WEST HALL

7:00 AM–7:45 AM

Complimentary Continental Breakfast

LEVEL 1, WEST HALL

7:45 AM–9:30 AM

Welcome and General Session 1: How We Should Be Screening and Novel Screening Techniques

LEVEL 2, BALLROOM

Amitabh Chak, MD—Chair

University Hospitals Case Medical Center

Cathy Eng, MD, FACP

The University of Texas MD Anderson Cancer Center

Welcome

Risk versus Cost: Should We Be Screening for Barrett's Esophagus?

Gary W. Falk, MD, MS

Perelman School of Medicine at University of Pennsylvania

Pro

Kenneth Wang, MD

Mayo Clinic

Con

Rebuttals

Naohisa Yahagi, MD, PhD

Keio University School of Medicine

Screening for Squamous Cell Carcinoma: The Japanese Perspective

William Grady, MD

Fred Hutchinson Cancer Research Center

Applications of Biomarkers in Screening and Surveillance

Panel Question and Answer

9:30 AM–10:00 AM

Break

10:00 AM–11:00 AM

Keynote Lectures: Microbial Pathogens and Malignancy

LEVEL 2, BALLROOM

Paul M. Lieberman, PhD

The Wistar Institute

Epstein-Barr Virus Biology and Its Carcinogenic Mechanisms

Keith T. Wilson, MD

Vanderbilt University Medical Center

Helicobacter Pylori–Induced Gastric Carcinogenesis: Molecular Mechanisms and Opportunities for Chemoprevention

Panel Question and Answer

11:00 AM–12:30 PM

General Session 2: Is There an Optimal Chemotherapy Regimen for Advanced Gastric Cancer? (ARS)

LEVEL 2, BALLROOM

This session uses audience response system (ARS) technology. See page 10 for instructions.

Manish A. Shah, MD—Co-Chair

Weill Cornell Medical College

Michael J. Weyant, MD—Co-Chair

University of Colorado, Denver

ABSTRACT 1: Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: A Chinese Western Cooperative Gastrointestinal Oncology Group study. First Author: Feng Bi (*Poster Session A, Board F1*)

Case Presentation

Salah-Eddin Al-Batran, MD

Institute of Clinical Cancer Research, UCT University Cancer Center Frankfurt

Optimal Therapy for Localized Disease

Yoon-Koo Kang, MD, PhD

Asan Medical Center, University of Ulsan College of Medicine

Optimal Therapy for Advanced Disease

Holly Gwen Prigerson, PhD
Weill Cornell Medical College
Palliative Care and Third-Line Chemotherapy

Panel Question and Answer

12:30 PM–2:00 PM

Poster Session A: Cancers of the Esophagus and Stomach

LEVEL 1, WEST HALL

Complimentary boxed lunch provided. See page 36 for a full listing of posters displayed in this session.

Posters by Topic

Prevention, Diagnosis, and Screening: *Poster Boards F8–G18*

Translational Research: *Poster Boards F6, G19–J11*

Multidisciplinary Treatment: *Poster Boards F1–F5, F7, J12–N22, O3–O16*

12:30 PM–2:00 PM

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

LEVEL 1, WEST HALL

Complimentary boxed lunch provided. See page 51 for a full listing of posters displayed in this session.

Posters by Topic

Translational Research: *Poster Boards O1–O2*

Multidisciplinary Treatment: *Poster Boards O3–O16*



12:45 PM–1:45 PM

Fellows, Residents, and Junior Faculty Networking Luncheon

LEVEL 3, ROOM 3014

See page 13 for more information on ticketed sessions.

George A. Fisher, MD, PhD—Co-Chair
Stanford University School of Medicine

Nipun B. Merchant, MD, FACS—Co-Chair
University of Miami Medical Center

Laura Dawson, MD
Princess Margaret Cancer Centre

Jennifer Rachel Eads, MD
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University

FELLOWS, RESIDENTS, AND JUNIOR FACULTY NETWORKING LUNCHEON, *continued*

Lee M. Ellis, MD

The University of Texas MD Anderson Cancer Center

William Grady, MD

Fred Hutchinson Cancer Research Center

Lisa A. Kachnic, MD, FASTRO

Vanderbilt University Medical Center

Shishir K. Maithel, MD

Winship Cancer Institute of Emory University

Robert C.G. Martin, II, MD, PhD, FACS

University of Louisville

Diane L. Reidy, MD

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

Manish A. Shah, MD

Weill Cornell Medical College

2:00 PM–3:30 PM

Oral Abstract Session: Cancers of the Esophagus and Stomach

LEVEL 2, BALLROOM

Prajnan Das, MD, MS, MPH—Co-Chair

The University of Texas MD Anderson Cancer Center

Ulysses Ribeiro, MD, PhD—Co-Chair

University of São Paulo

ABSTRACT 3: NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.

First Author: Somnath Mukherjee (*Poster Session A, Board F3*)

ABSTRACT 4: Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).

First Author: Peter C. Enzinger (*Poster Session A, Board F4*)

ABSTRACT 5: A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).

First Author: Yoon-Koo Kang (*Poster Session A, Board F5*)

Discussion: Daniel V.T. Catenacci, MD
The University of Chicago

ABSTRACT 6: Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.
First Author: Dung T. Le (*Poster Session A, Board F6*)

ABSTRACT 7: Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475).
First Author: Toshihiko Doi (*Poster Session A, Board F7*)

Discussion: Marcus H. Moehler, MD, PhD
Johannes-Gutenberg University Mainz

Panel Question and Answer

3:30 PM–4:00 PM
Break

4:00 PM–5:30 PM
General Session 3: Multimodal Approaches for Advanced Gastroesophageal Junction Cancers—Challenging Cases from the United States and Europe versus Asia (ARS)

LEVEL 2, BALLROOM

This session uses audience response system (ARS) technology. See page 10 for instructions.

Daniel V.T. Catenacci, MD—Co-Chair
The University of Chicago

Heinz-Josef Lenz, MD, FACP—Co-Chair
USC Norris Comprehensive Cancer Center

ABSTRACT 2: A western validation of a novel gastric cancer prognostic model using American data.
First Author: Bryan S. Goldner (*Poster Session A, Board F2*)

Case Presentation

Yuko Kitagawa, MD, PhD, FACS
Keio University School of Medicine
Eastern Perspective: Surgeon

Atsushi Ohtsu, MD, PhD
Exploratory Oncology Research & Clinical Trial Center, National Cancer Center
Eastern Perspective: Medical Oncologist

GENERAL SESSION 3, continued

Prajnan Das, MD, MS, MPH

The University of Texas MD Anderson Cancer Center
Western Perspective: Radiation Oncologist

Brian D. Badgwell, MD

The University of Texas MD Anderson Cancer Center
Western Perspective: Surgeon

Jennifer Rachel Eads, MD

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University
Western Perspective: Medical Oncologist

Panel Question and Answer

5:30 PM–7:00 PM

Poster Session A: Cancers of the Esophagus and Stomach (Continued) and Networking Reception

LEVEL 1, WEST HALL

Complimentary wine and cheese provided. See page 36 for a full listing of posters displayed in this session.

5:30 PM–7:00 PM

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach (Continued) and Networking Reception

LEVEL 1, WEST HALL

Complimentary wine and cheese provided. See page 51 for a full listing of posters displayed in this session.

5:45 PM–6:45 PM

Poster Walks

LEVEL 1, WEST HALL

Meet at the Poster Assistance Desk.

Poster Walk Leader: Eric Van Cutsem, MD, PhD

University Hospital Gasthuisberg

Poster Walk Leader: Ulysses Ribeiro, MD, PhD

University of São Paulo

6:00 PM–7:00 PM

Breakout Sessions

Breakout Session: Mechanical Palliation in Advanced Gastroesophageal Cancer

LEVEL 3, ROOM 3014

Ulysses Ribeiro, MD, PhD

University of São Paulo
Surgery

Felice Schnoll-Sussman, MD

Weill Cornell Medical College, New York-Presbyterian Hospital
Endoscopic Therapy

Panel Question and Answer

Breakout Session: Rare Tumors of the Upper GI Tract

LEVEL 3, ROOM 3020

Jennifer Rachel Eads, MD

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University
GIST and Neuroendocrine Tumors

Panel Question and Answer

Juan W. Valle

University of Manchester, The Christie Hospital
Bile Duct Cancer

Panel Question and Answer

Friday, January 22

6:30 AM–7:55 AM

Complimentary Continental Breakfast

LEVEL 1, WEST HALL

7:00 AM–7:00 PM

Exhibits Open

LEVEL 1, WEST HALL

6:55 AM–7:55 AM

Breakout Sessions

Breakout Session: Fighting Cancer With Big Data—Using Population Data to Improve Outcomes

LEVEL 3, ROOM 3020

Margaret T. Mandelson, PhD, MPH

Virginia Mason Medical Center

Fighting Cancer with Big Data: Using Population Data to Improve Outcomes

Panel Question and Answer

Breakout Session: Recent Advances in Treatment of Neuroendocrine Tumors

LEVEL 3, ROOM 3014

Pamela L. Kunz, MD

Stanford University School of Medicine

New Options for Neuroendocrine Tumors: Results of Recent Trials

Lisa Bodei, MD

European Institute of Oncology

Rationale for Peptide Receptor Radiation Therapy

Dik J. Kwekkeboom, MD, PhD

Erasmus University Medical Center

The Rotterdam Experience: Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Panel Question and Answer

7:55 AM–9:30 AM

Welcome and General Session 4: Innovative Approaches to Hepatopancreatobiliary Disease (ARS)

LEVEL 2, BALLROOM

This session uses audience response system (ARS) technology. See page 10 for instructions.

Sarah E. Hoffs, MD—Co-Chair

Moffitt Cancer Center

Shishir K. Maithel, MD, FACS—Co-Chair

Winship Cancer Institute of Emory University

George A. Fisher, MD, PhD

Stanford University School of Medicine

Welcome

Case Presentation #1

Robert A. Wolff, MD

The University of Texas MD Anderson Cancer Center

Pro: Neoadjuvant Therapy

Nipun B. Merchant, MD, FACS

University of Miami Medical Center

Con: Neoadjuvant Therapy

Case Question Follow Up and Rebuttals

Case Presentation #2

Joseph M. Herman, MD, MSc

Johns Hopkins University School of Medicine

Stereotactic Body Radiation Therapy as Neoadjuvant Therapy

Robert C.G. Martin, II, MD, PhD, FACS

University of Louisville

Innovative Surgical Option: Irreversible Electroporation

Panel Question and Answer

9:30 AM–10:00 AM

Break

10:00 AM–11:00 AM

Keynote Lecture: Inflammatory Networks and Cancer Immune Surveillance

LEVEL 2, BALLROOM

Robert H. Vonderheide, MD, DPhil

Abramson Cancer Center of the University of Pennsylvania

Inflammatory Networks and Cancer Immune Surveillance

Panel Question and Answer

11:00 AM–12:30 PM

General Session 5: Pancreatic Cancer—An International Dialogue About Patterns of Care and Their Impact on Outcomes

LEVEL 2, BALLROOM

Jorge Gallardo, MD—Co-Chair

Centro Oncología Clínica Alemana

Vincent J. Picozzi, MD, MMM—Co-Chair

Virginia Mason Medical Center

ABSTRACT 191: Resected pancreatic cancer (PC): Impact of adjuvant therapy (Rx) at a high-volume center (HVC) on overall survival (OS).

First Author: Margaret T. Mandelson (*Poster Session B, Board A1*)

Introduction

James L. Abbruzzese, MD, FACP

Duke University

Academic Center

Michael Seiden, MD, PhD

McKesson Specialty Health

Community Perspective

Ricardo Rossi, MD

Centro Oncología Clínica Alemana

International Perspective

Wolff H. Schmiegel, MD, PhD

Ruhr-University Bochum

International Perspective

Panel Question and Answer

12:30 PM–2:00 PM

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

LEVEL 1, WEST HALL

Complimentary boxed lunch provided. See page 53 for a full listing of posters displayed in this session.

Posters by Topic

Prevention, Diagnosis, and Screening: Poster Boards A8–B15,

Translational Research: Poster Boards A5–A7, B16–E13, N15–N22

Multidisciplinary Treatment: Poster Boards A1–A4, E14–N13, O1–O15

12:30 PM–2:00 PM

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

LEVEL 1, WEST HALL

Complimentary boxed lunch provided. See page 77 for a full listing of posters displayed in this session.

Posters by Topic

Prevention, Diagnosis, and Screening: Poster Board N14

Multidisciplinary Treatment: Poster Boards N15–N22

Translational Research: Poster Boards O1–O15

12:45 PM–1:45 PM

Poster Walks

LEVEL 1, WEST HALL

Meet at the Poster Assistance Desk.

Poster Walk Leader: Boris Blechacz, MD, PhD

The University of Texas MD Anderson Cancer Center

Poster Walk Leader: Tushar Patel, MBChB

Mayo Clinic

2:00 PM–3:30 PM

Oral Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

LEVEL 2, BALLROOM

Jordan Berlin, MD—Co-Chair

Vanderbilt-Ingram Cancer Center

Vincent J. Picozzi, MD, MMM—Co-Chair

Virginia Mason Medical Center

ORAL ABSTRACT SESSION, *continued*

ABSTRACT 193: Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study. First Author: Eric Van Cutsem (*Poster Session B, Board A3*)

ABSTRACT 194: NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.

First Author: Jonathan R. Strosberg (*Poster Session B, Board A4*)

ABSTRACT 195: PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.

First Author: Dung T. Le (*Poster Session B, Board A5*)

Discussion: **Bertram Wiedenmann, MD, PhD**
Charité University Hospital, Berlin

ABSTRACT 197: Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).

First Author: Lorenza Rimassa (*Poster Session B, Board A7*)

Discussion: **Boris Blechacz, MD, PhD**
The University of Texas MD Anderson Cancer Center

Panel Question and Answer

3:30 PM–4:00 PM

Break

4:00 PM–5:30 PM

General Session 6: Hepatocellular Carcinoma Tumor Board (ARS)

LEVEL 2, BALLROOM

This session uses audience response system (ARS) technology. See page 10 for instructions.

Steven N. Hochwald, MD—Co-Chair
Roswell Park Cancer Institute

Tushar Patel, MBChB—Co-Chair
Mayo Clinic

ABSTRACT 192: Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). First Author: Ghassan K. Abou-Alfa (*Poster Session B, Board A2*)

Julie Heimbach, MD
Mayo Clinic
Transplant Surgeon

Theodore S. Hong, MD

Massachusetts General Hospital
Radiation Oncologist

David C. Madoff, MD, FSIR, FACR

Weill Cornell Medical College
Interventional Oncologist

Richard S. Finn, MD

Ronald Regan UCLA Medical Center
Medical Oncologist

Panel Question and Answer

5:30 PM–7:00 PM

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract (Continued) and Networking Reception

LEVEL 1, WEST HALL

Complimentary wine and cheese provided. See page 53 for a full listing of posters displayed in this session.

5:30 PM–7:00 PM

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract (Continued) and Networking Reception

LEVEL 1, WEST HALL

Complimentary wine and cheese provided. See page 77 for a full listing of posters displayed in this session.

6:00 PM–7:00 PM

Breakout Session: Perspectives on Physician Aid in Dying (ARS)

LEVEL 2, BALLROOM

This session uses audience response system (ARS) technology. See page 10 for instructions.

George A. Fisher, MD, PhD—Chair

Stanford University School of Medicine

Lynne Patricia Taylor, MD

Virginia Mason Medical Center
Death with Dignity: Fulfilling a Need

Kavitha Ramchandran, MD

Stanford University School of Medicine
Potential Pitfalls in the Process

Panel Question and Answer

Saturday, January 23

6:30 AM–7:55 AM

Complimentary Continental Breakfast

LEVEL 1, WEST HALL

6:55 AM–7:55 AM

Breakout Sessions

Breakout Session: Multiplex Approach to Colon Cancer Testing—Is It Ready for Prime Time?

LEVEL 3, ROOM 3014

James M. Ford, MD

Stanford University School of Medicine

Multiplex Approach to Colon Cancer Testing: Is It Ready for Prime Time?

Panel Question and Answer

Breakout Session: The Importance of Recognizing Microsatellite Instability Tumors—Cancer Prevention and New Options for Treatment

LEVEL 3, ROOM 3020

Zsofia Kinga Stadler, MD

Memorial Sloan Kettering Cancer Center

The Importance of Microsatellite Instability Screening

Dung T. Le, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

PD1 Antibody for Microsatellite Instability–High Tumors

Panel Question and Answer

7:00 AM–7:55 AM

Poster Session C: Cancers of the Colon, Rectum, and Anus

LEVEL 1, WEST HALL

See page 80 for a full listing of posters displayed in this session.

Posters by Topic

Prevention, Diagnosis, and Screening: Poster Boards A1, A4, A8–D1

Multidisciplinary Treatment: Poster Boards A2–A3, A5–A6, G15–O2

Translational Research: Poster Boards A7, D2–G14

7:00 AM–7:55 AM

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

LEVEL 1, WEST HALL

See page 105 for a full listing of posters displayed in this session.

Posters by Topic

Translational Research: Poster Boards O3–O6

Multidisciplinary Treatment: Poster Boards O7–O21

7:55 AM–9:30 AM

Welcome and General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer

LEVEL 2, BALLROOM

Andrew T. Chan, MD, MPH—Co-Chair

Massachusetts General Hospital

Rodrigo Jover, MD, PhD—Co-Chair

Alicante General University Hospital

Bertram Wiedenmann, MD, PhD

Charité University Hospital, Berlin

Welcome

ABSTRACT 488: Early detection of colorectal neoplasia: Combination of eight cancer-associated blood-based protein biomarkers.

First Author: Ib J. Christensen (*Poster Session C, Board A1*)

Linda Rabeneck, MD, MPH, FRCPC

Cancer Care Ontario and The University of Toronto

Colorectal Cancer Screening: Global Disparities in Resources and Approaches

Michael Bretthauer, MD, PhD

University of Oslo

Controversies in Surveillance After Adenoma and Colorectal Cancer Diagnosis

Douglas K. Rex, MD, MACP, MACG, FASGE, AGAF

Indiana University School of Medicine

Novel Endoscopic Screening Approaches

Carolyn C. Compton, MD, PhD

Arizona State University and Mayo Clinic

Complexities of Pathologic Assessment of Adenomas and Serrated Polyps

Panel Question and Answer

9:30 AM–10:00 AM

Break

10:00 AM–11:00 AM

Keynote Lectures: Global Overview of Colorectal Cancer—Past, Present, and Future

LEVEL 2, BALLROOM

David Cunningham, MD, FRCP, FMedSci

The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research

Global Overview of Colon Cancer

Daniel G. Haller, MD, FACP, FRCP

Abramson Cancer Center of the University of Pennsylvania

Global Overview of Rectal Cancer

Panel Question and Answer

11:00 AM–12:30 PM

General Session 8: Diverse International Perspectives on the Work-up and Management of Rectal Cancer

LEVEL 2, BALLROOM

Regina G.H. Beets-Tan, MD, PhD—Co-Chair

The Netherlands Cancer Institute

Vincenzo Valentini, MD, Professor—Co-Chair

Università Cattolica S. Cuore

Case Presentation

Gina Brown, MD

The Royal Marsden NHS Foundation Trust

Endoscopic Ultrasonography versus MRI for Staging and Response Evaluation

Claus Roedel, MD

University of Frankfurt

Short-Course versus Long-Course Chemoradiation Therapy

Philip Paty, MD

Memorial Sloan Kettering Cancer Center

Surgical Options for Low Rectal Cancer

Bengt Glimelius, Professor, MD, PhD

Uppsala University

Chemotherapy for Rectal Cancer: When Is It Beneficial?

Panel Question and Answer

12:30 PM–2:00 PM

Poster Session C: Cancers of the Colon, Rectum, and Anus (Continued)

LEVEL 1, WEST HALL

Complimentary boxed lunch provided. See page 80 for a full listing of posters displayed in this session.

12:30 PM–2:00 PM

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus (Continued)

LEVEL 1, WEST HALL

Complimentary boxed lunch provided. See page 105 for a full listing of posters displayed in this session.

1:00 PM–1:45 PM

Poster Walks

LEVEL 1, WEST HALL

Meet at the Poster Assistance Desk.

Poster Walk Leader: Pamela L. Kunz, MD

Stanford University School of Medicine

Poster Walk Leader: Sarah E. Hoffe, MD

Moffitt Cancer Center

2:00 PM–3:30 PM

Oral Abstract Session: Cancers of the Colon, Rectum, and Anus

LEVEL 2, BALLROOM

Daniel Chang, MD—Co-Chair

Stanford University School of Medicine

Eunice L. Kwak, MD, PhD—Co-Chair

Massachusetts General Hospital

ABSTRACT 489: Neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer: Results of a Polish II multicentre phase III study.

First Author: Krzysztof Bujko (*Poster Session C, Board A2*)

ORAL ABSTRACT SESSION, *continued*

ABSTRACT 490: ACCORD12/0405-Prodigie 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up.

First Author: Eric Francois (*Poster Session C, Board A3*)

ABSTRACT 491: The incidence of secondary pelvic tumors after previous (chemo)radiation for rectal cancer.

First Author: Anouk J.M. Rombouts (*Poster Session C, Board A4*)

Discussion: Claus Roedel, MD

University of Frankfurt

ABSTRACT 492: Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

First Author: Johanna C. Bendell (*Poster Session C, Board A5*)

ABSTRACT 493: MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).

First Author: Heinz-Josef Lenz (*Poster Session C, Board A6*)

Discussion: Wells A. Messersmith, MD

University of Colorado Cancer Center

Panel Question and Answer

3:30 PM–4:00 PM

Break

4:00 PM–5:30 PM

General Session 9: Difficult Cases in Rectal Cancer (ARS)

LEVEL 2, BALLROOM

This session uses audience response system (ARS) technology. See page 10 for instructions.

Karyn A. Goodman, MD, MS—Co-Chair

University of Colorado School of Medicine

Diane L. Reidy, MD—Co-Chair

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

Case Presentation

Neil Howard Segal, MD, PhD

Memorial Sloan Kettering Cancer Center
Medical Oncologist Perspective

Nancy N. Baxter, MD, PhD, FRCS

St. Michael's Hospital
Surgeon Perspective

Lisa A. Kachnic, MD, FASTRO

Vanderbilt University Medical Center
Radiation Oncologist Perspective

Alan P. Venook, MD

University of California, San Francisco
Medical Oncologist Perspective

Panel Question and Answer

Poster Sessions Directory

Thursday, January 21

12:30 PM–2:00 PM and 5:30 PM–7:00 PM

Poster Session A: Cancers of the Esophagus and Stomach

LEVEL 1, WEST HALL

Posters by Topic

Prevention, Diagnosis, and Screening: *Poster Boards F8–G18*

Translational Research: *Poster Boards F6, G19–J11*

Multidisciplinary Treatment: *Poster Boards F1–F5, F7, J12–N22, O3–O16*

- BOARD F1:** Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: A Chinese Western Cooperative Gastrointestinal Oncology Group study. (Abstract 1)
First Author: Feng Bi
- BOARD F2:** A western validation of a novel gastric cancer prognostic model using American data. (Abstract 2)
First Author: Bryan S. Goldner
- BOARD F3:** NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. (Abstract 3)
First Author: Somnath Mukherjee
- BOARD F4:** Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naïve metastatic esophagogastric adenocarcinoma (MEGA). (Abstract 4)
First Author: Peter C. Enzinger
- BOARD F5:** A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). (Abstract 5)
First Author: Yoon-Koo Kang
- BOARD F6:** Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. (Abstract 6)
First Author: Dung T. Le
- BOARD F7:** Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). (Abstract 7)
First Author: Toshihiko Doi

- BOARD F8:** Evaluation of state comprehensive cancer control plans for content related to stomach cancer. (Abstract 8)
First Author: James Randolph Hillard
- BOARD F9:** The ratio of major and minor axis by EUS as a possible predictive marker for the diagnosis of submucosal invasive gastric cancer. (Abstract 9)
First Author: Jae Jin Hwang
- BOARD F10:** C-reactive protein at 4 days after surgery as an early predictor of serious infectious complications following esophageal cancer surgery. (Abstract 10)
First Author: Kazuki Kano
- BOARD F11:** Staging of gastric cancer: Comparison of post-operative pathologic staging to pre-operative CT and endoscopic ultrasonographic staging. (Abstract 11)
First Author: Sung Min Jung
- BOARD F12:** The examination of appropriate surveillance after resection of GIST from 115 recurrent patients. (Abstract 12)
First Author: Noriko Wada
- BOARD F13:** Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent. (Abstract 13)
First Author: Yuji Toiyama
- BOARD F14:** Preoperative prediction of peritoneal metastasis in gastric cancer as an indicator for neoadjuvant treatment. (Abstract 14)
First Author: Koichiro Mori
- BOARD F15:** Clinical outcome of endoscopic submucosal dissection versus surgery for patients with early gastric cancer. (Abstract 15)
First Author: Ki-Nam Shim
- BOARD F16:** Survival and prognosticators of gastric cancer patients with only positive peritoneal lavage cytology. (Abstract 16)
First Author: Kazuki Kano
- BOARD F17:** Circulating biomarkers exploratory study in loco-regional gastroesophageal adenocarcinoma patients. (Abstract 17)
First Author: Federico Longo
- BOARD F18:** An observational study evaluating the expression of HER2 (1+, 2+, and 3+) with HLA A2/A3+ in gastric adenocarcinoma patients. (Abstract 18)
First Author: Ashis Patnaik
- BOARD F19:** Impact of sarcopenia on short- and long-term outcomes in patients with gastric cancer. (Abstract 19)
First Author: Fumiko Hirata

POSTER SESSION A, *continued*

- BOARD F20:** Obesity and mortality in patients with esophageal cancer: A systematic review and meta-analysis. (Abstract 20)
First Author: Arjun Gupta
- BOARD F21:** Clinical outcomes of patients enrolled in clinical trial compared with patients outside clinical trial in advanced gastric cancer. (Abstract 21)
First Author: Jaejoon Han
- BOARD F22:** The accuracy of endoscopic ultrasonography for identifying stomach neoplasm before endoscopic submucosal dissection. (Abstract 22)
First Author: Pil Hun Song
- BOARD G1:** The usefulness of condom method EUS for esophageal mass evaluation. (Abstract 23)
First Author: Jeong Seop Moon
- BOARD G2:** Establishment and validation of prognostic nomograms including HER2 status in metastatic gastric cancer. (Abstract 24)
First Author: Takeshi Kawakami
- BOARD G3:** The value of endoscopic ultrasonography in a PET/CT upfront model in staging esophageal cancer with respect to treatment decision. (Abstract 25)
First Author: Jan-Binne Hulshoff
- BOARD G4:** Sensitivity and specificity of signs and symptoms to determine the risk of death associated with gastric cancer patients. (Abstract 26)
First Author: Gustavo A. Rojas Uribe
- BOARD G5:** Sarcopenia with modified Glasgow prognostic score as a predictor of long-term survival in patients with gastric cancer. (Abstract 27)
First Author: Masaaki Nishi
- BOARD G6:** Risk factors of gastric carcinogenesis in underlying gastric mucosal atrophy. (Abstract 28)
First Author: Ji Hyun Song
- BOARD G7:** The influence of venous thromboembolism on prognosis of esophageal cancer patients. (Abstract 29)
First Author: En Amada
- BOARD G8:** Concordance of HER2 status between local and central review in gastric and gastroesophageal junction cancers: A French observational study of 394 specimens (HERable study). (Abstract 30)
First Author: Genevieve Monges-Ranchin
- BOARD G9:** Reduction of tumor metabolism is associated with prognosis of advanced gastric cancer patients treated with palliative chemotherapy: Prospective cohort study. (Abstract 31)
First Author: Seongyeol Park

- BOARD G10:** Perioperative decrement of factor XIII as a predictor of anastomotic leakage after esophagectomy in patients with esophageal cancer. (Abstract 32)
First Author: Hiroya Takeuchi
- BOARD G11:** Economic burden of advanced gastric cancer (AGC) in Taiwan. (Abstract 33)
First Author: Jihyung Hong
- BOARD G12:** Preoperative accuracy of gastric cancer staging in patient selection for neoadjuvant therapy. (Abstract 34)
First Author: Naruhiko Ikoma
- BOARD G13:** Staging laparoscopy with cytology analysis in gastric cancer. (Abstract 35)
First Author: Naruhiko Ikoma
- BOARD G16:** The influence of perioperative decreasing total psoas area on prognosis of esophageal cancer patients. (Abstract 38)
First Author: Yuki Hirata
- BOARD G17:** The influence of tumor location, histology, and patient ethnicity on the accuracy of EUS in staging gastric and gastroesophageal junction (GEJ) cancers. (Abstract 39)
First Author: Andy Z. Huang
- BOARD G18:** The outcome of surgical treatment for oldest-old patients with gastric cancer. (Abstract 40)
First Author: Makoto Hikage
- BOARD G19:** Correlation between change of FA score and postoperative recurrence in esophageal cancer patients who received neoadjuvant treatment. (Abstract 41)
First Author: Satoru Matsuda
- BOARD G20:** Pathological heterogeneity after trastuzumab and combination chemotherapy in HER2+ gastroesophageal adenocarcinoma xenograft. (Abstract 42)
First Author: Connie Yip
- BOARD G21:** The role of mTOR inhibitors in targeting a putative cancer stem cell-like population in esophageal cancer. (Abstract 43)
First Author: Da Wang
- BOARD G22:** Pilot trial of CRLX101 in patients (pts) with advanced, chemotherapy-refractory gastroesophageal cancer (GEC). (Abstract 44)
First Author: Joseph Chao
- BOARD H1:** Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (Abstract 45)
First Author: Gyorgy Bodoky

POSTER SESSION A, *continued*

- BOARD H2:** The effects of HOXB7 in the promotion of migration, invasion and anti-apoptosis in gastric cancer. (Abstract 46)
First Author: Moon Kyung Joo
- BOARD H3:** Expression of ERCC1, TUBB3, BRCA1, and TS as predictive markers of neoadjuvant chemotherapy for squamous cell carcinoma of the esophagus. (Abstract 47)
First Author: Toshiyasu Ojima
- BOARD H4:** Association of the immune checkpoint molecule expression with neutrophil-lymphocyte ratio in patients with gastric cancer: A retrospective study. (Abstract 48)
First Author: Hiroaki Tanaka
- BOARD H5:** Peripheral trafficking of bone marrow-derived stem cells in patients with different types of gastric neoplasms: Significance of complement and interleukins. (Abstract 49)
First Author: Wojciech Blogowski
- BOARD H6:** TGF- β inhibitor LY2157299 (galunisertib) in combination with standard chemotherapy to inhibit signaling to pSmad and EMT and to suppress tumor growth in gastric cancer. (Abstract 50)
First Author: Sawako Miyoshi
- BOARD H7:** Correlation of pretreatment p63-positive subtype of gastroesophageal adenocarcinoma (GEAC) with pathologic complete response (pathCR) in patients receiving preoperative chemoradiation. (Abstract 51)
First Author: Elena Elimova
- BOARD H8:** Case review for ramucirumab as a single agent in our hospital. (Abstract 52)
First Author: Satoshi Murahashi
- BOARD H9:** Clinical outcomes of three-dimensional versus two-dimensional laparoscopic surgery for gastric cancer: A single center, prospective, randomized trial—An interim report. (Abstract 53)
First Author: Jian-Xian Lin
- BOARD H10:** Esophageal cancer in young patients: Is aggressive treatment associated with better outcomes? (Abstract 54)
First Author: Alexander D. Glaser
- BOARD H11:** Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for advanced gastric cancer: A single center, prospective, randomized trial. (Abstract 55)
First Author: Jian-Xian Lin
- BOARD H12:** Effect of combined consideration of distinct signatures of VEGF and soluble VEGFR2 on prognostic implication in gastric cancer. (Abstract 56)
First Author: Chan-Young Ock

- BOARD H13:** Whole exome sequencing and gene expression profiling of neuroendocrine carcinoma in the stomach. (Abstract 57)
First Author: Rie Makuuchi
- BOARD H14:** Molecular mechanism of secondary-resistant for trastuzumab in gastric cancer. (Abstract 58)
First Author: Masaaki Iwatsuki
- BOARD H15:** Palliative treatment of obstructive esophageal cancer by vascular targeted photodynamic therapy (VTP): Preclinical study in orthotopic rat model. (Abstract 59)
First Author: Ronny Uzana
- BOARD H16:** Microarray analysis of gene expression in gastric cancer cells from ascitic fluids before and after capecitabine and oxaliplatin (CapeOX). (Abstract 60)
First Author: Osamu Maeda
- BOARD H17:** Correlation of the prognostic impact of Ki67/BCL2 index based on immunohistochemistry with poor clinical outcome in gastric cancer. (Abstract 61)
First Author: Byoung Kwan Son
- BOARD H18:** The therapeutic effect of irreversible electroporation ablation in mouse model of gastrointestinal cancer. (Abstract 62)
First Author: Hyuk Soon Choi
- BOARD H19:** Prognostic impact of tumor-associated B-cells and plasma cells in esophageal and gastric adenocarcinoma. (Abstract 63)
First Author: Richard Fristedt
- BOARD H20:** Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG). (Abstract 64)
First Author: Sonia Yip
- BOARD H21:** Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). (Abstract 65)
First Author: Seung Kim
- BOARD H22:** Comprehensive genomic profiling (CGP) to assess mutational load in gastric and esophageal adenocarcinomas: Implications for immunotherapies. (Abstract 66)
First Author: Garrett Michael Frampton
- BOARD J1:** Impact of 18F-fluorodeoxyglucose position emission tomography/computed tomography on radiotherapy treatment planning and outcomes in esophageal cancer. (Abstract 67)
First Author: Sweet Ping Ng
- BOARD J2:** Characterization of a novel regulator of AKT/mTOR signaling in gastric cancer. (Abstract 68)
First Author: Shikha Satendra Singh

POSTER SESSION A, *continued*

- BOARD J3:** Clinical significance of MET amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum (FP) combination chemotherapy. (Abstract 69)
First Author: Seyoung Seo
- BOARD J4:** Fiducial markers vs. PET/CT for esophageal cancer GTV delineation for radiotherapy treatment planning using a standard SUV threshold and background uptake method. (Abstract 70)
First Author: Jasmine A. Oliver
- BOARD J5:** The clinical trial for photodynamic diagnosis mediated 5-ALA for peritoneal metastasis due to advanced gastric cancer. (Abstract 71)
First Author: Tsuyoshi Takahashi
- BOARD J6:** Gene expression profiling of Japanese gastric cancer patients using Asian Cancer Research Group classification. (Abstract 72)
First Author: Masanori Terashima
- BOARD J7:** Inverse correlation between expression and methylation of RPRM, a TP53 dependent G2 arrest mediator candidate, along the gastric precancerous cascade. (Abstract 73)
First Author: Alejandro Hernan Corvalan
- BOARD J8:** KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma. (Abstract 74)
First Author: Les Henderson
- BOARD J10:** Effect of MiR-32 on gastric carcinoma tumorigenesis by targeting Kruppel-like factor 4. (Abstract 76)
First Author: Chao Yan
- BOARD J11:** Mir-935 to suppress gastric signet ring cell carcinoma tumorigenesis by targeting Notch1 expression. (Abstract 77)
First Author: Chao Yan
- BOARD J12:** The prognostic factor and the optimal timing of conversion surgery in unresectable stage IV gastric cancer: A retrospective analysis. (Abstract 78)
First Author: Tamotsu Sagawa
- BOARD J13:** Risk factors for loss of lean body mass after gastrectomy for gastric cancer. (Abstract 79)
First Author: Toru Aoyama
- BOARD J14:** The recurrence patterns and post-recurrence survivals in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with preoperative paclitaxel/cisplatin-based chemoradiotherapy. (Abstract 80)
First Author: Hung-Yang Kuo

- BOARD J15:** A phase II study of neoadjuvant chemotherapy with a modified FOLFOX6 regimen for locally advanced gastric cancer. (Abstract 81)
First Author: Xiang Wang
- BOARD J16:** Body mass index to predict the long-term outcomes of advanced gastric cancer. (Abstract 82)
First Author: Jae Gyu Kim
- BOARD J17:** Safety and efficacy of endoscopic spray cryotherapy for esophageal cancer. (Abstract 83)
First Author: Franklin C. Tsai
- BOARD J18:** Phase II study of neoadjuvant epirubicin(E), cisplatin(C) and 5-fluorouracil(F) followed by chemoradiation with selective surgical resection/salvage for carcinomas of the esophagus and esophagogastric junction. (Abstract 84)
First Author: Joseph C. Poen
- BOARD J19:** Effects of perioperative enteral EPA-enriched immunonutrition on meaningful loss of lean body mass after total gastrectomy for gastric cancer: Post hoc analysis of a phase III study. (Abstract 85)
First Author: Takaki Yoshikawa
- BOARD J20:** Epidemiology and survival of metastatic gastrointestinal stromal tumor: A Surveillance, Epidemiology, and End Results (SEER) database review. (Abstract 86)
First Author: Srinath Sundararajan
- BOARD K1:** Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer. (Abstract 87)
First Author: Jae J. Kim
- BOARD K2:** Outcomes and toxicity in patients treated with bimodality or trimodality therapy for esophageal carcinoma with intensity modulated radiation therapy (IMRT). (Abstract 88)
First Author: Ajay Patel
- BOARD K3:** Changes of weight and body composition after gastrectomy in the elderly gastric cancer patients. (Abstract 89)
First Author: Kenki Segami
- BOARD K4:** Alteration of recurrence patterns and prognostic factors by adjuvant S-1 monotherapy in patients with stage II/III gastric cancer. (Abstract 90)
First Author: Mitsuro Kanda
- BOARD K5:** Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma. (Abstract 91)
First Author: Daxuan Hao
- BOARD K6:** Perioperative chemotherapy in locally advanced gastric cancer in Chile: From evidence to daily practice. (Abstract 92)
First Author: Bettina G. Müller

POSTER SESSION A, *continued*

- BOARD K7:** Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer by textural features derived from pretreatment FDG-PET scans. (Abstract 93)
First Author: Jorn Beukinga
- BOARD K8:** Multimodal analgesia combined with intravenous administration of acetaminophen in perioperative management of esophagectomy using modified ERAS protocol. (Abstract 94)
First Author: Takashi Ogata
- BOARD K9:** Adjuvant chemotherapy with or without concurrent radiotherapy in stage IB patients with gastric cancer: Subgroup analysis of the adjuvant chemoradiotherapy in stomach tumors (ARTIST) phase III trial. (Abstract 95)
First Author: Haa-na Song
- BOARD K10:** Clinicopathological features of ruptured GIST in the ReGISTry study of high risk GIST patients after complete resection in Japan. (Abstract 96)
First Author: Toshirou Nishida
- BOARD K11:** Prognostic analysis of esophageal squamous cell cancer patients who received neoadjuvant chemoradiotherapy combined with surgery. (Abstract 97)
First Author: Xue Li
- BOARD K12:** Evaluation of preventive factors for postoperative pulmonary complications following esophagectomy for T1bN0M0 cancer using data from JCOG0502. (Abstract 98)
First Author: Isao Nozaki
- BOARD K13:** Notch and wnt-beta catenin pathways as targets of γ -secretase inhibitor IX (GSI) mediated therapy in CD44+ gastric cancer (GC) cells. (Abstract 99)
First Author: Ruben R. Plentz
- BOARD K14:** Management of dysphagia in esophageal cancer (EC): A population-based study. (Abstract 100)
First Author: Sameh Mikhail
- BOARD K15:** Nimotuzumab in combination with preoperative concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A prospective trial. (Abstract 101)
First Author: Xiaoyuan Wu
- BOARD K16:** Is there a role for neoadjuvant radiation dose escalation in esophageal cancer? A meta-analysis. (Abstract 102)
First Author: Laila Lobo
- BOARD K17:** Role of nutritional status as predictor of survival in oesophageal cancer treated with definitive chemoradiation (dCRT): outcome from SCOPE1, a phase II/III randomised trial of dCRT +/- cetuximab. (Abstract 103)
First Author: Samantha Cox

- BOARD K18:** Ten year experience of esophageal endoscopic submucosal dissection of superficial esophageal neoplasms in a single center. (Abstract 104)
First Author: Hyungchul Park
- BOARD K19:** Subset of patients with unfavorable T1N2-3M0 gastric cancer for whom surgery alone is the standard treatment. (Abstract 105)
First Author: Yukio Maezawa
- BOARD K20:** Survival benefit of additional surgery after non-curative endoscopic resection in patients with early gastric cancer. (Abstract 106)
First Author: Keun Won Ryu
- BOARD K21:** Efficacy and safety of endoscopic resection for gastric subepithelial tumors. (Abstract 107)
First Author: Kyoungwon Jung
- BOARD K22:** Second-line chemotherapy with paclitaxel for elderly patients with advanced gastric cancer. (Abstract 108)
First Author: Akihiro Ohba
- BOARD L1:** Retrospective comparison of long-term outcomes in patients with stage II/III (UICC-TNM6th) esophageal squamous cell carcinoma treated with 60 Gy or 50.4 Gy of definitive chemoradiotherapy with fluorouracil and platinum. (Abstract 109)
First Author: Hidekazu Hirano
- BOARD L2:** Endoscopic stenting for esophageal leak after minimally invasive esophagectomy. (Abstract 110)
First Author: Brenda Ernst
- BOARD L3:** Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+ relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). (Abstract 111)
First Author: Johanna C. Bendell
- BOARD L4:** Outcomes of surgical intervention in gastric carcinoid disease. (Abstract 112)
First Author: Ann Falor Callahan
- BOARD L5:** Efficacy and safety of irinotecan monotherapy as third line treatment for advanced gastric cancer. (Abstract 113)
First Author: Takeshi Kawakami
- BOARD L6:** Role of palliative resection in patients with incurable advanced gastric cancer unfit for chemotherapy. (Abstract 114)
First Author: Wataru Takagi
- BOARD L7:** Phase I study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for gastric cancer with peritoneal metastasis. (Abstract 115)
First Author: Daisuke Kobayashi

POSTER SESSION A, *continued*

- BOARD L8:** Follow-up data from a phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1 based chemoradiotherapy for advanced gastric cancer. (Abstract 116)
First Author: Hyun-Jeong Shim
- BOARD L9:** Survival outcome of metastatic adenocarcinoma of esophagogastric junction in the trastuzumab era. (Abstract 117)
First Author: Yukiya Narita
- BOARD L10:** Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer. (Abstract 118)
First Author: Somnath Mukherjee
- BOARD L11:** On-trial radiotherapy quality assurance in NeoSCOPE: A randomised phase II trial of chemoradiotherapy in oesophageal cancer. (Abstract 119)
First Author: Elin Evans
- BOARD L12:** Impact of preoperative sarcopenia on recurrence in gastric cancer surgery. (Abstract 120)
First Author: Tsutomu Sato
- BOARD L13:** Outcomes of esophagectomy in elderly patients with esophageal cancer: A population-based study. (Abstract 121)
First Author: Sameh Mikhail
- BOARD L14:** Response to neoadjuvant chemotherapy and impact on survival for resected gastric cancer. (Abstract 122)
First Author: Erin Greenleaf
- BOARD L15:** Timing of adjuvant chemotherapy and impact on survival for resected gastric cancer. (Abstract 123)
First Author: Erin Greenleaf
- BOARD L16:** Neoadjuvant and adjuvant, floxuridine, leucovorin, oxaliplatin, and docetaxel (FLOD) in patients with locally advanced operable gastroesophageal adenocarcinoma: A phase II study with pathologic responses and long term follow-up. (Abstract 124)
First Author: Bach Ardalan
- BOARD L17:** Patterns of radiotherapy and its impact on survival in patients with locally advanced gastric and gastroesophageal junction adenocarcinoma: Before and after the publication of the MAGIC trial. (Abstract 125)
First Author: Chi Lin
- BOARD L18:** Transthoracic anastomotic leak after esophagectomy: Still a catastrophe? (Abstract 126)
First Author: Martin McCarter

- BOARD L20:** A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: OGS1203 (HERBIS-5). (Abstract 128)
First Author: Kazuhiro Nishikawa
- BOARD L22:** A multinational phase II clinical trial of neoadjuvant imatinib for large gastrointestinal stromal tumor of the stomach. (Abstract 130)
First Author: Han-Kwang Yang
- BOARD M1:** Impact of comorbidity in the choice of curative treatment for esophageal cancer: A population-based study. (Abstract 131)
First Author: Zohra Faiz
- BOARD M2:** Course and predictors of postoperative outcomes in older patients with localized gastric adenocarcinoma treated preoperatively. (Abstract 132)
First Author: Nikolaos Charalampakis
- BOARD M3:** Multidisciplinary approach for cT1bN0 esophageal cancer. (Abstract 133)
First Author: Toshiro Iizuka
- BOARD M4:** Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) failed to imatinib and sunitinib therapy. (Abstract 134)
First Author: Nai-Jung Chiang
- BOARD M5:** Efficacy and feasibility of neoadjuvant chemotherapy and chemoradiotherapy for elderly patients with stage IB/II/III (excluding T4) esophageal cancer: Retrospective study. (Abstract 135)
First Author: Takahiro Miyamoto
- BOARD M6:** Feasibility of the combination chemotherapy with 5-fluorouracil and oxaliplatin in metastatic gastric or colorectal cancer patients more than age of 80. (Abstract 136)
First Author: Kyu-Hyoung Lim
- BOARD M7:** T-shaped linear-stapled intrathoracic esophagogastric anastomosis for minimally invasive Ivor Lewis esophagectomy. (Abstract 137)
First Author: Yinan Dong
- BOARD M8:** Radiofrequency ablation for pulmonary metastases from esophageal squamous cell carcinoma. (Abstract 138)
First Author: Hironobu Shigaki
- BOARD M9:** Evaluation of the effects of neoadjuvant therapy on stage specific outcome estimates in patients with completely resected gastric cancer. (Abstract 139)
First Author: Michael C. Lowe
- BOARD M10:** FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors. (Abstract 140)
First Author: Johanna C. Bendell

POSTER SESSION A, *continued*

- BOARD M11:** Is there clinical and prognostic heterogeneity among subtypes of advanced gastric cancer? (Abstract 141)
First Author: Teresa Garcia
- BOARD M12:** Prognostic factors for survival in patients with advanced gastric cancer treated with chemotherapy. (Abstract 142)
First Author: Montserrat Mangas
- BOARD M13:** Real world treatment patterns of previously treated advanced gastric and gastroesophageal junction adenocarcinoma (GC) in Mexico. (Abstract 143)
First Author: Kyla Jones
- BOARD M14:** Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater. (Abstract 144)
First Author: Pat Gulhati
- BOARD M15:** A proposal for the management guideline of superficial esophageal squamous cell carcinoma: After endoscopic resection. (Abstract 145)
First Author: Yong Chan Lee
- BOARD M16:** The prognostic significance of perineural invasion in patients with esophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy. (Abstract 146)
First Author: Ankur Kaushik Patel
- BOARD M17:** Prospective results of perioperative chemotherapy (PCT) with cisplatin and irinotecan for locally advanced gastric cancer. (Abstract 147)
First Author: Guilherme Luiz Stelko Pereira
- BOARD M18:** Survival analysis in gastric cancer patients of the Colombian coffee zone at the Oncologos del Occidente clinic during 2014. (Abstract 148)
First Author: Gustavo A. Rojas Uribe
- BOARD M19:** Readmission after robotic Ivor Lewis esophagectomy: Earlier discharge, increased readmissions? (Abstract 149)
First Author: Ahmed Salem
- BOARD M20:** Prognostic value of 18F-FDG PET/CT metabolic tumor volume for complete pathologic response and clinical outcomes after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. (Abstract 150)
First Author: Puja Venkat
- BOARD M21:** Small caliber covered self expanding metal stents in the management of malignant dysphagia. (Abstract 151)
First Author: Steven Kucera
- BOARD M22:** Trastuzumab induced cardiotoxicity in HER2-positive metastatic esogastric cancers. (Abstract 152)
First Author: Jerome Martin-Babau

- BOARD N1:** S-1 in combination with docetaxel and oxaliplatin (DOS) every 2 weeks (DOS2w) or every 3 weeks (DOS3w) in patients with advanced gastro-esophageal adenocarcinoma (aGEA): Final results of 2 parallel phase I studies. (Abstract 153)
First Author: Camilla Qvortrup
- BOARD N2:** Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. (Abstract 154)
First Author: Elizabeth Catherine Smyth
- BOARD N3:** Impact of anatomical location of positive lymph node on TNM classification in patients with node positive gastric cancer. (Abstract 155)
First Author: Masanori Tokunaga
- BOARD N4:** Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST). (Abstract 156)
First Author: George D. Demetri
- BOARD N5:** Pathologic and clinical outcomes in cT2N0 esophageal cancer: A cohort study. (Abstract 157)
First Author: Gauri Bhuchar
- BOARD N6:** Pattern of regional recurrence after curative resection in locally advanced adenocarcinoma of gastroesophageal junction: Implication for elective lymphatic target delineation of radiotherapy. (Abstract 158)
First Author: Jiajia Zhang
- BOARD N7:** Outcomes in patients with brain metastasis from esophageal carcinoma. (Abstract 159)
First Author: Nadia Saeed
- BOARD N8:** Recurrence patterns and outcome of patients with stage IIIB-IV(M0) gastric cancer after gastrectomy and adjuvant chemotherapy: A retrospective analysis in one Chinese cancer center. (Abstract 160)
First Author: Chun-Xia Du
- BOARD N9:** Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059. (Abstract 161)
First Author: Charles S. Fuchs
- BOARD N10:** Risk Factors for Survival in Early T Stage Gastric Cancer. (Abstract 162)
First Author: Naruhiko Ikoma
- BOARD N11:** Accuracy of clinical staging with EUS for early stage esophageal cancer: Are we denying patients beneficial neoadjuvant chemo-radiation? (Abstract 163)
First Author: Carrie Luu

POSTER SESSION A, *continued*

- BOARD N12:** Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer. (Abstract 164)
First Author: Rebecca Barbara Goody
- BOARD N13:** Bone loss and vitamin D deficiency post gastrectomy for gastro-esophageal malignancy. (Abstract 165)
First Author: Kiran Virik
- BOARD N14:** Correlation of locoregional treatment failures with radiotherapy target volumes after radiochemotherapy for esophageal cancer. (Abstract 166)
First Author: Cihan Gani
- BOARD N15:** Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. (Abstract 167)
First Author: Hyun Cheol Chung
- BOARD N16:** Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer. (Abstract 168)
First Author: Tomohiro Nishina
- BOARD N17:** Analysis and follow-up of the patients diagnosed with metastatic gastric adenocarcinoma in the Parc Taulí Hospital, Sabadell, between 2010 and 2013. (Abstract 169)
First Author: Marta Ferrer
- BOARD N18:** Factors predictive of tumor recurrence and overall survival in patients with esophageal cancer who have pathologic complete response after neo-adjuvant therapy. (Abstract 170)
First Author: Alexandra Gangi
- BOARD N19:** Outcomes of minimally invasive versus open esophagectomy for esophageal cancer: A single-center case-control study. (Abstract 171)
First Author: Hugo Miguel Teixeira Ferraz Dos Santos Sousa
- BOARD N20:** Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in locally advanced esophageal cancer. (Abstract 172)
First Author: Joseph A. Clara
- BOARD N21:** Patterns and predictors of locoregional recurrence following neoadjuvant chemoradiation for esophageal cancer. (Abstract 173)
First Author: Aaron Udell Blackham
- BOARD N22:** Trimodality treatment for locally advanced esophageal malignancies. (Abstract 174)
First Author: Tarita Thomas

12:30 PM–2:00 PM and 5:30 PM–7:00 PM

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

LEVEL 1, WEST HALL

Posters by Topic

Translational Research: *Poster Boards 01–02*

Multidisciplinary Treatment: *Poster Boards 03–016*

- BOARD 01:** Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival. (Abstract TPS175)
First Author: Takashi Kojima
- BOARD 02:** An investigator sponsored phase Ia/Ib trial of selinexor in combination with irinotecan in patients with adenocarcinoma of stomach and distal esophagus. (Abstract TPS176)
First Author: Heloisa P. Soares
- BOARD 03:** Phase II trial of bolus 5-FU/LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502). (Abstract TPS177)
First Author: Tetsuhito Muranaka
- BOARD 04:** A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). (Abstract TPS178)
First Author: Charles S. Fuchs
- BOARD 05:** Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection compared with standard gastrectomy with lymphadenectomy in early gastric cancer: A study protocol of a multicenter randomized phase III clinical trial (SENIORITA trial). (Abstract TPS179)
First Author: Keun Won Ryu
- BOARD 06:** Multicenter phase II study of neoadjuvant chemotherapy consisted with S-1 and oxaliplatin followed by gastrectomy for locally advanced gastric cancer. (Abstract TPS180)
First Author: Yoshihiro Okita
- BOARD 08:** A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastro-esophageal junction cancer (TOXAG study). (Abstract TPS182)
First Author: Huseyin Abali
- TBOARD 09:** Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. (Abstract TPS183)
First Author: Atsushi Ohtsu

TRIALS IN PROGRESS POSTER SESSION A, *continued*

- BOARD O10:** Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study. (Abstract TPS184)
First Author: Charles S. Fuchs
- BOARD O11:** KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (Abstract TPS185)
First Author: Josep Tabernero
- BOARD O12:** A phase II study of laparoscopic hyperthermic intraperitoneal chemoperfusion (HIPEC) for gastric carcinomatosis or positive cytology. (Abstract TPS186)
First Author: Brian D. Badgwell
- BOARD O13:** PLATFORM: Planning treatment of oesophago-gastric (OG) cancer—A randomised maintenance therapy trial. (Abstract TPS187)
First Author: Catherine Cafferkey
- BOARD O14:** Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial. (Abstract TPS188)
First Author: Do-Youn Oh
- BOARD O15:** Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study. (Abstract TPS189)
First Author: Manish A. Shah
- BOARD O16:** Phase II/III randomized trial of exclusive chemoradiotherapy with or without dose escalation in locally advanced esophageal carcinoma: The CONCORDE study (PRODIGE 26). (Abstract TPS190)
First Author: Gilles Crehange

12:30 PM–2:00 PM and 5:30 PM–7:00 PM

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

LEVEL 1, WEST HALL

Posters by Topic

Prevention, Diagnosis, and Screening: *Poster Boards A8–B15*

Translational Research: *Poster Boards A5–A7, B16–E13, N15–N22*

Multidisciplinary Treatment: *Poster Boards A1–A4, E14–N13, O1–O15*

- BOARD A1:** Resected pancreatic cancer (PC): Impact of adjuvant therapy (Rx) at a high-volume center (HVC) on overall survival (OS). (Abstract 191)
First Author: Margaret T. Mandelson
- BOARD A2:** Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). (Abstract 192)
First Author: Ghassan K. Abou-Alfa
- BOARD A3:** Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study. (Abstract 193)
First Author: Eric Van Cutsem
- BOARD A4:** NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. (Abstract 194)
First Author: Jonathan R. Strosberg
- BOARD A5:** PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. (Abstract 195)
First Author: Dung T. Le
- BOARD A6:** A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer. (Abstract 196)
First Author: Tanios Bekaii-Saab
- BOARD A7:** Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC). (Abstract 197)
First Author: Lorenza Rimassa
- BOARD A8:** Accuracy of AASLD guidelines for pre-operative diagnosis of hepatocellular carcinoma in a surgical population. (Abstract 198)
First Author: Edwin Yang

POSTER SESSION B, *continued*

- BOARD A9:** Resectability assessment of enhanced CT and contrast-enhanced endoscopic ultrasonography for the periampullary neoplasm. (Abstract 199)
First Author: Pengfei Yu
- BOARD A10:** Angiogenic gene expression in primary neuroendocrine tumors and their metastases. (Abstract 200)
First Author: Tanja Milosavljevic
- BOARD A11:** The optimal time-interval to re-resection for incidentally discovered gallbladder cancer: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. (Abstract 201)
First Author: Cecilia Grace Ethun
- BOARD A12:** A novel pathology-based preoperative risk score to predict distant and locoregional residual disease and survival for incidentally discovered gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium. (Abstract 202)
First Author: Cecilia Grace Ethun
- BOARD A13:** Small bowel neuroendocrine tumors: A critical analysis of diagnostic work-up and operative approach. (Abstract 203)
First Author: Cecilia Grace Ethun
- BOARD A14:** Noninvasive markers to predict malignant intraductal papillary mucinous neoplasms of the pancreas. (Abstract 204)
First Author: Sonia Tewani Orcutt
- BOARD A15:** Molecular diagnosis with the 92-Gene Assay (92-GA) and decision-impact on treatment: Final results from a prospective, multi-disciplinary study. (Abstract 205)
First Author: Sachdev P. Thomas
- BOARD A16:** Identification of prognostic value of lymphocyte-to-monocyte ratio in patients with advanced HBV-associated hepatocellular carcinoma. (Abstract 206)
First Author: Zhan-Hong Chen
- BOARD A17:** Adjunctive role of preoperative liver magnetic resonance imaging added to computed tomography among resected pancreatic cancer patients. (Abstract 207)
First Author: Hyoung Woo Kim
- BOARD A18:** Age barrier in clinical trials: Are we truly moving forward? (Abstract 208)
First Author: Olubukola Ayodele
- BOARD A19:** Presentation, clinical behavior, outcomes and therapies for patients with advanced pancreas adenocarcinoma (PAC) who present with or develop ascites. (Abstract 209)
First Author: Angel Mier Hicks

- BOARD A20:** Significance of lymph node metastasis in pancreatic neuroendocrine tumors. (Abstract 210)
First Author: Katsunobu Taki
- BOARD A21:** The prognostic value of stroma desmoplasia in pancreatic ductal adenocarcinoma. (Abstract 211)
First Author: Emmanouil Fokas
- BOARD A22:** Conditional survival probability of long-term survival after resection of peri-hilar cholangiocarcinoma. (Abstract 212)
First Author: Stefan Buettner
- BOARD B1:** Recurrent feature after radiofrequency ablation therapy for hepatocellular carcinoma: Risk of increasing malignant behavior. (Abstract 213)
First Author: Shinichiro Yamada
- BOARD B2:** Does metabolic tumor volume predict tumor regression grade after neoadjuvant therapy for borderline resectable pancreatic cancer? (Abstract 214)
First Author: Will Jin
- BOARD B3:** Irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): A single institution experience. (Abstract 215)
First Author: Manojkumar Bupathi
- BOARD B4:** Pancreatic cancer: Survival in clinical trials versus the real world. (Abstract 216)
First Author: Reith Roy Sarkar
- BOARD B5:** Impact of sarcopenia evaluated using the total psoas area (TPA) in patients undergoing Y-90 radioembolization for hepatocellular carcinoma (HCC). (Abstract 217)
First Author: Pericles Ioannides
- BOARD B6:** Risk factor of thrombosis and impact on prognosis in patients with pancreatic cancer receiving chemotherapy. (Abstract 218)
First Author: Kazunaga Ishigaki
- BOARD B7:** Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up. (Abstract 219)
First Author: Elettra Merola
- BOARD B8:** Pancreatic squamous cell carcinoma: Epidemiology, clinicopathologic characteristics, and outcomes. (Abstract 220)
First Author: Oxana V. Makarova-Rusher
- BOARD B9:** Recurrence rates of resected appendix carcinoid tumors: A 20-year experience at Memorial Sloan Kettering Cancer Center. (Abstract 221)
First Author: Jennifer Murphy

POSTER SESSION B, *continued*

- BOARD B10:** Diagnostic potential of mucins in pancreatic juice for pancreatic cancer. (Abstract 222)
First Author: Asish Patel
- BOARD B11:** Interim results of a screening protocol for early detection of pancreatic cancer in asymptomatic high-risk patients. (Abstract 223)
First Author: Alexandra Gangi
- BOARD B12:** Lymph node metastases in the prognosis of gastroenteropancreatic neuroendocrine tumors. (Abstract 224)
First Author: Jacob Andrew Martin
- BOARD B13:** Prevalence of radiologic evidence of metastatic pancreatic ductal adenocarcinoma (PDAC) at first post-operative restaging studies in patients (pts) undergoing pancreatic cancer surgery with curative intent. (Abstract 225)
First Author: Sofia Palacio
- BOARD B14:** A reappraisal of staging laparoscopy in three subtypes of cholangiocarcinoma: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium. (Abstract 226)
First Author: Jesse Davidson
- BOARD B15:** Does receptor status impact survival of patients with mid-gut neuroendocrine tumors? (Abstract 227)
First Author: Yi-Zarn Wang
- BOARD B16:** Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years. (Abstract 228)
First Author: Gillian G. Baptiste
- BOARD B17:** Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial. (Abstract 229)
First Author: Masatoshi Kudo
- BOARD B18:** A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial. (Abstract 230)
First Author: Lauren McLendon Postlewait
- BOARD B19:** A multi-center study of 349 pancreatic mucinous cystic neoplasms: Preoperative risk factors for adenocarcinoma. (Abstract 231)
First Author: Lauren McLendon Postlewait
- BOARD B20:** Effect of regorafenib on angiogenesis in neuroendocrine tumors in vitro. (Abstract 232)
First Author: Tanja Milosavljevic
- BOARD B21:** Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma? (Abstract 233)
First Author: Chanjuan Shi

- BOARD B22:** Stereotactic body radiation therapy for pancreatic cancer: Assessing motion with and without abdominal compression. (Abstract 234)
First Author: Priscilla K. Stumpf
- BOARD C1:** Non-invasive monitoring of patient-derived orthotopic xenograft: An optimal system for rapid in vivo testing. (Abstract 235)
First Author: Mayrim V. Rios Perez
- BOARD C2:** Auranofin to prevent progression of pancreatic ductal adenocarcinoma. (Abstract 236)
First Author: Mayrim V. Rios Perez
- BOARD C3:** Early tumor shrinkage as a predictor of favorable outcomes in patients (pts) with advanced pancreatic cancer treated with FOLFIRINOX. (Abstract 237)
First Author: Yasuhiro Kaga
- BOARD C4:** The anticancer effects of supinoxin (RX-5902) in pancreatic carcinoma. (Abstract 238)
First Author: Young Lee
- BOARD C5:** Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following SBRT. (Abstract 239)
First Author: Kamran A. Ahmed
- BOARD C6:** Genomically adjusted radiation dose to predict for survival with adjuvant radiation in resectable pancreatic cancer. (Abstract 240)
First Author: Tobin Joel Crill Strom
- BOARD C7:** A new immunohistochemistry prognostic score (IPS) for recurrence and survival in pancreatic neuroendocrine tumors (PanNET). (Abstract 241)
First Author: Antonio Viudez
- BOARD C8:** Systemic treatment patterns in small bowel and appendiceal adenocarcinomas (SBA and AA): A population-based study. (Abstract 242)
First Author: Jaclyn Marie Beca
- BOARD C9:** Impact and mechanistic role of MicroRNA-1291 on pancreatic tumorigenesis. (Abstract 243)
First Author: Mei-Juan Tu
- BOARD C10:** Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA). (Abstract 244)
First Author: Talia Golan
- BOARD C11:** The use of plasma microRNAs to predict toxicity following liver stereotactic body radiation therapy. (Abstract 245)
First Author: Kyle Clifford Cuneo

POSTER SESSION B, *continued*

- BOARD C12:** Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): A study using MSK-IMPACT. (Abstract 246)
First Author: Nitya Prabhakar Raj
- BOARD C13:** Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC). (Abstract 247)
First Author: Hui-Li Wong
- BOARD C14:** Assessment of hyaluronic acid in tumor microenvironment (TME) of intrahepatic cholangiocarcinoma (CCA). (Abstract 248)
First Author: Leslie Jane Padrnos
- BOARD C15:** Molecular pathways associated with micro-vascular invasion HCC. (Abstract 249)
First Author: Caroline Yun Ling Chia
- BOARD C16:** Genomic landscape of pancreatic adenocarcinoma: Does age matter?
(Abstract 250)
First Author: Irit Ben-Aharon
- BOARD C17:** A pooled analysis of long pentraxin for patients with advanced pancreatic cancer.
(Abstract 251)
First Author: Mitsuhito Sasaki
- BOARD C18:** BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC. (Abstract 252)
First Author: Mohamed Bouattour
- BOARD C19:** Whole-exome tumor sequencing study in patients with biliary cancer with a response to MEK inhibitors. (Abstract 253)
First Author: Daniel H. Ahn
- BOARD C20:** Association of long-term survival in pancreatic cancer (PDAC) with increased proliferative and anti-apoptotic protein activation. (Abstract 254)
First Author: Vincent J. Picozzi
- BOARD D1:** A multi-institutional analysis of duodenal neuroendocrine tumors: Tumor biology rather than extent of resection to dictate prognosis. (Abstract 255)
First Author: Georgios A. Margonis
- BOARD D2:** Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17. (Abstract 256)
First Author: Shelly Sud
- BOARD D3:** Tumor profiling of 431 pancreatic tumors from elderly patients. (Abstract 257)
First Author: Joanne Xiu

- BOARD D4:** Expression and prognostic significance of human epidermal growth factor receptors 1, 2, and 3 by histological type in periampullary adenocarcinoma. (Abstract 258)
First Author: Jacob Elebro
- BOARD D5:** Synergy of water soluble prodrug triptolide (minnelide) with gemcitabine and nab-paclitaxel in pancreatic cancer. (Abstract 259)
First Author: Vikas Dudeja
- BOARD D6:** Precision cancer therapy through nanoparticle delivery of siRNA against KRAS. (Abstract 260)
First Author: Matthew S. Strand
- BOARD D7:** Assessment of genomic alterations in adenosquamous carcinoma of the pancreas (ASCOP). (Abstract 261)
First Author: Emmet Jordan
- BOARD D8:** Evaluation of triptolide pro-drug (Minnelide) as an anti-stromal and anti-tumoral therapeutic option for pancreatic cancer. (Abstract 262)
First Author: Sulagna Banerjee
- BOARD D9:** Retrospective study of non-mucinous appendiceal adenocarcinomas: Role of systemic chemotherapy and cytoreductive surgery. (Abstract 263)
First Author: Marc Isamu Uemura
- BOARD D10:** The mitochondrial metabolism inhibitor CPI-613 in combination with mFOLFIRINOX for pancreatic adenocarcinoma. (Abstract 264)
First Author: Angela Tatiana Alistar
- BOARD D12:** Correlation of high density of CD8+ and FoxP3+ lymphocytes with overall survival in intestinal-type periampullary adenocarcinoma. (Abstract 266)
First Author: Carl Fredrik Warfvinge
- BOARD D13:** Prognostic significance of tumor infiltrating natural killer cells in periampullary adenocarcinoma. (Abstract 267)
First Author: Sebastian Lundgren
- BOARD D14:** Preliminary observations of blood-based (BB) molecular testing in a subset of patients with pancreatic cancer (PDA) participating in the Know Your Tumor (KYT) initiative. (Abstract 268)
First Author: Michael J. Pishvaian
- BOARD D15:** PANOVA: A pilot study of TTFIELDS concomitant with gemcitabine for front-line therapy in patients with advanced pancreatic adenocarcinoma. (Abstract 269)
First Author: Fernando Rivera

POSTER SESSION B, *continued*

- BOARD D16:** Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC). (Abstract 270)
First Author: Austin G. Duffy
- BOARD D17:** Antitumor activity and immune response in CD40 immunotherapy with gemcitabine and nab-paclitaxel in an orthotopic pancreatic cancer mouse model. (Abstract 271)
First Author: Despina Siolas
- BOARD D18:** Molecular prescreening (MP) to treat patients (pts) with advanced pancreatic cancer (PC) in early clinical trials. (Abstract 272)
First Author: Tamara Sauri
- BOARD D19:** The role of myeloid derived suppressor cells in cholangiocarcinoma: A potential target for therapy. (Abstract 273)
First Author: Richard Francis Dunne
- BOARD D20:** Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN). (Abstract 274)
First Author: Chantal Dreyer
- BOARD D21:** DNA sequencing to identify potentially novel targets for therapy in pancreatic cancer. (Abstract 275)
First Author: Jeffrey Toll
- BOARD D22:** Blood neuroendocrine tumor gene cluster analysis to predict somatostatin analog response. (Abstract 276)
First Author: Mark S. Kidd
- BOARD E1:** High frequency irreversible electroporation (H-FIRE) as a novel method of targeted cell death. (Abstract 277)
First Author: Imran A. Siddiqui
- BOARD E2:** Adding targeted inhibition of PI3K and MAPK signaling pathways to standard chemotherapy in experimental pancreatic cancer. (Abstract 278)
First Author: Niranjana Awasthi
- BOARD E3:** The Know Your Tumor (KYT) initiative: A national program of multi-omic molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA). (Abstract 279)
First Author: Anitra Engebretson
- BOARD E4:** Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1 α —Final results of the ALICE-2 study. (Abstract 280)
First Author: Luca Faloppi

- BOARD E5:** Effect of intratumoral CD3+ and NKp46+ cells on tumor progression in resected colorectal liver metastases treated with neoadjuvant chemotherapy. (Abstract 281)
First Author: Matteo Donadon
- BOARD E6:** Multi-Omic profiling (MoP) for patients (pts) with pancreatic cancer (PDA): Initial results of the Know Your Tumor (KYT) initiative. (Abstract 282)
First Author: Michael J. Pishvaian
- BOARD E7:** Molecular profiling of advanced biliary cancer: Lost in translation from bench to bedside. (Abstract 283)
First Author: Mark Doherty
- BOARD E8:** A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC). (Abstract 284)
First Author: Safi Shahda
- BOARD E9:** Comprehensive genomic analysis in metastatic pancreatic ductal adenocarcinoma (PDAC). (Abstract 285)
First Author: Hui-Li Wong
- BOARD E10:** Next-generation sequencing (NGS) in an advanced hepatocellular carcinoma (HCC) cohort: Analyses of TP53 and CTNNB1. (Abstract 286)
First Author: Robin Kate Kelley
- BOARD E11:** Next Generation Sequencing (NGS) to reveal mutations in IDH1 and its effect on patient (pt) outcomes in advanced biliary tract cancer (aBTC) who received gemcitabine and cisplatin (GC). (Abstract 287)
First Author: Daniel H. Ahn
- BOARD E12:** Stromal characterization of small bowel adenocarcinomas. (Abstract 288)
First Author: Katrina Pedersen
- BOARD E13:** PD-1/PD-L1 expression and molecular associations in HPB malignancies. (Abstract 289)
First Author: Kabir Mody
- BOARD E14:** Lymphatic invasion as an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1. (Abstract 290)
First Author: Keisuke Kazama
- BOARD E15:** Intra and extrahepatic cholangiocarcinoma: An evaluation of adjuvant therapy. (Abstract 291)
First Author: Jeff Wiisanen
- BOARD E16:** Myeloid deprived suppressive cell to mediate the prognostic value of neutrophil to hemoglobin ratio for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. (Abstract 292)
First Author: Xing Li

POSTER SESSION B, *continued*

- BOARD E17:** Did multiagent chemotherapy improve clinical outcomes of advanced pancreatic cancer? A single center experience of 408 cases. (Abstract 293)
First Author: Yousuke Nakai
- BOARD E18:** Effect of ablative radiotherapy on survival in patients with inoperable intrahepatic cholangiocarcinoma: A dose response analysis. (Abstract 294)
First Author: Christopher H. Crane
- BOARD E19:** Long term outcome in patients with advanced malignant peritoneal mesothelioma (AbM) treated with a pemetrexed/platin combination. (Abstract 295)
First Author: Meinolf Karthaus
- BOARD E21:** Second-line chemotherapy by FOLFIRINOX with unresectable pancreatic cancer (phase I, II study). (Abstract 297)
First Author: Noritoshi Kobayashi
- BOARD E20:** PET-CT compared to no PET-CT in the management of potentially resectable colorectal cancer liver metastases: The costs implications of a randomized controlled trial. (Abstract 296)
First Author: Pablo Emilio Serrano Aybar
- BOARD E22:** Clinicopathological features and response to platinum-based chemotherapy in pancreatic neuroendocrine carcinoma: A retrospective multicenter study of 70 patients. (Abstract 298)
First Author: Susumu Hijioka
- BOARD F1:** Aggressive surgery for advanced colorectal liver metastases in the era of multidisciplinary approaches. (Abstract 299)
First Author: Yoshihiro Mise
- BOARD F2:** Emibetuzumab plus ramucirumab: Simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study. (Abstract 300)
First Author: James J. Harding
- BOARD F4:** The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinoma. (Abstract 302)
First Author: Young Saing Kim
- BOARD F3:** Phase II study of fixed dose-rate gemcitabine plus S-1 as second-line treatment in advanced biliary tract cancer. (Abstract 301)
First Author: Satoshi Kobayashi
- BOARD F5:** Development of a multidisciplinary program for evaluation and treatment of pancreatic cancer in a community healthcare system. (Abstract 303)
First Author: Robert C. Hermann

- BOARD F6:** Prognostic influence of clinical biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) receiving sorafenib: A single institution experience. (Abstract 304)
First Author: Omar Abdel-Rahman
- BOARD F7:** Prognosis of unresectable hepatocellular carcinoma: Comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. (Abstract 305)
First Author: Feng Jin Zhang
- BOARD F8:** Comparative effectiveness of FOLFIRINOX (FOL) versus gemcitabine and nab-paclitaxel (GNP) for the first-line treatment of metastatic pancreatic cancer. (Abstract 306)
First Author: Wei-Han Cheng
- BOARD F9:** Randomized clinical trial of the effect of simo decoction plus acupuncture and chewing gum on postoperative ileus in patients with hepatocellular carcinoma after hepatic resection. (Abstract 307)
First Author: Jian-Hong Zhong
- BOARD F10:** Efficacy of chemotherapy in patients with pancreatic acinar cell carcinoma. (Abstract 308)
First Author: Changhoon Yoo
- BOARD F11:** Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover. (Abstract 309)
First Author: Eric Raymond
- BOARD F12:** Treatment of pancreatic ductal adenocarcinoma (PDAC) by argyrin F (AF) + gemcitabine (G). (Abstract 310)
First Author: Ruben R. Plentz
- BOARD F13:** Effect of adjuvant (AD) radiotherapy (RT) on outcomes following pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PDA): A margin-stratified analysis. (Abstract 311)
First Author: Lee Mayer Ocuin
- BOARD F14:** Peri-operative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PDAC): A pilot study. (Abstract 312)
First Author: Robert de Wilton Marsh
- BOARD F15:** Outcomes of multimodality therapy for gallbladder cancer in the United States (US): Analysis of the National Cancer Data Base (NCDB). (Abstract 313)
First Author: Fatima Hamid
- BOARD F16:** Valproate as a novel radiosensitizer in selective internal radiation therapy (SIRT) for unresectable hepatocellular carcinoma. (Abstract 314)
First Author: Kenneth Chin

POSTER SESSION B, *continued*

- BOARD F17:** Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial. (Abstract 315)
First Author: Simron Singh
- BOARD F18:** Chemotherapy versus best supportive care in patients with advanced biliary tract carcinoma: A propensity score-matched analysis. (Abstract 316)
First Author: Jun Ho Ji
- BOARD F19:** Pancreas resection for unresectable locally advanced pancreatic cancer (LAPC): Resection rate in the era of FOLFIRINOX and GEM+nabPTX. (Abstract 317)
First Author: Shinichiro Takahashi
- BOARD F20:** Feasibility and impact on resectability of FOLFIRINOX in locally-advanced and borderline pancreatic cancer. (Abstract 318)
First Author: Fabienne Portales
- BOARD F21:** Utility of a multidisciplinary tumor board in the management of pancreatic diseases. (Abstract 319)
First Author: David G. Brauer
- BOARD F22:** Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas. (Abstract 320)
First Author: Michael J. Pishvaian
- BOARD G1:** Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression. (Abstract 321)
First Author: J. Bart Rose
- BOARD G2:** Stereotactic body radiotherapy for unresectable hepatocellular carcinoma: A population based analysis of tumors up to 15 cm. (Abstract 322)
First Author: Rosanna Yeung
- BOARD G3:** Unresectable hepatocellular carcinoma: Is radio-embolization an alternative for chemo-embolization? (Abstract 323)
First Author: Laila Lobo
- BOARD G4:** Rates and patterns of recurrence following complete resection of Hilar cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Consortium. (Abstract 324)
First Author: Harveshp Mogal
- BOARD G6:** Effect of preoperative bilirubin on outcomes of completely resected hilar cholangiocarcinoma: A multi-institutional analysis. (Abstract 326)
First Author: Harveshp Mogal

- BOARD G7:** A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC). (Abstract 327)
First Author: Lin Shen
- BOARD G8:** Neoadjuvant nab-paclitaxel and gemcitabine (AG) in borderline resectable (BR) or unresectable (UR) locally advanced pancreatic adenocarcinoma (LAPC) in patients ineligible for FOLFIRINOX. (Abstract 328)
First Author: Shawn Peterson
- BOARD G9:** Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC). (Abstract 329)
First Author: Masatoshi Kudo
- BOARD G10:** Adjuvant therapy in pancreatic adenocarcinoma: A systemic review and meta-analysis. (Abstract 330)
First Author: Kazi Jannatun Nahar
- BOARD G11:** Treatment patterns and clinical outcomes of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs). (Abstract 331)
First Author: Xiaolong Jiao
- BOARD G13:** Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC). (Abstract 333)
First Author: David Goldstein
- BOARD G14:** A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer. (Abstract 334)
First Author: David Bing Zhen
- BOARD G15:** A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. (Abstract 335)
First Author: Milind M. Javle
- BOARD G16:** Gallbladder cancer presenting with jaundice: Uniformly fatal or still potentially curable? (Abstract 336)
First Author: Thuy Tran
- BOARD G17:** The characteristics of pancreatic neck cancer. (Abstract 337)
First Author: Hiroki Yamaue
- BOARD G18:** Safety and feasibility of enhanced recovery after surgery in the patients underwent pancreaticoduodenectomy for hepatobiliary and pancreatic malignancy. (Abstract 338)
First Author: Keisuke Kazama

POSTER SESSION B, *continued*

- BOARD G19:** Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers. (Abstract 339)
First Author: Nicholas Gerard Berger
- BOARD G20:** Survival of pancreaticoduodenectomies with venous reconstruction using a population-based database. (Abstract 340)
First Author: Bryan S. Goldner
- BOARD G21:** A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer. (Abstract 341)
First Author: Manuel Hidalgo
- BOARD G22:** An institutional analysis of gemcitabine and capecitabine for advanced biliary cancer. (Abstract 342)
First Author: Shipra Gandhi
- BOARD H2:** Risk factors of chemotherapy-induced nausea and vomiting in patients with advanced pancreatic cancer receiving modified FOLFIRINOX. (Abstract 344)
First Author: Akira Shinohara
- BOARD H3:** Intrahepatic cholangiocarcinoma: Ambitious operations and outcomes. (Abstract 345)
First Author: Mustafa Raouf
- BOARD H4:** Incorporating trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcinoma: A single center experience. (Abstract 346)
First Author: Alexander Y. Kim
- BOARD H5:** Comparison of a new prognostic system and other three current staging systems in predicting the survival rate of patients with HBV-associated advanced hepatocellular carcinoma. (Abstract 347)
First Author: Ying-Fen Hong
- BOARD H6:** Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review. (Abstract 348)
First Author: Edmond Mankee Chan
- BOARD H7:** Comprehensive analysis of radiographic, clinical, and inflammatory markers demonstrating changes in lean muscle correlate with outcome in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) who undergo taxane-based chemotherapy (CT). (Abstract 349)
First Author: Daniel H. Ahn
- BOARD H8:** Comparative effectiveness of combination TACE/ablation vs. monotherapy in hepatocellular carcinoma. (Abstract 350)
First Author: Arthur Winer

- BOARD H9:** Is neoadjuvant chemoradiation important in borderline resectable pancreatic cancer (BRPC)? Clinical and surgical outcomes associated with preoperative FOLFIRINOX alone in BRPC. (Abstract 351)
First Author: Sunhee S. Kim
- BOARD H10:** Risk factors of hospital mortality after initial hepatic resection among patients with primary hepatocellular carcinoma. (Abstract 352)
First Author: Hong-Gui Qin
- BOARD H11:** Phase I study of neoadjuvant S-1 plus cisplatin with concurrent radiation for biliary tract cancer (KOBTC02). (Abstract 353)
First Author: Osamu Itano
- BOARD H12:** Splenic radiation during pancreatic cancer radiotherapy: Are we throwing the baby out with the bath water? (Abstract 354)
First Author: Awalpreet Singh Chadha
- BOARD H13:** Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. (Abstract 355)
First Author: Young Saing Kim
- BOARD H14:** The impact of maximum tumor shrinkage of primary site (MTSP) by FOLFIRINOX in the first-line treatment of pancreatic cancer. (Abstract 356)
First Author: Kei Saito
- BOARD H15:** A phase II study of biweekly gemcitabine at fixed dose rate infusion plus S1 as first-line chemotherapy in patients with locally advanced or metastatic pancreatic cancer. (Abstract 357)
First Author: Xj Xiang
- BOARD H16:** Impact of hepatic function and tumor extent on survival in patients with unresectable hepatocellular carcinoma treated with liver-directed therapies. (Abstract 358)
First Author: Marisa E. Hill
- BOARD H18:** Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. (Abstract 360)
First Author: Alexander V. Kirichenko
- BOARD H19:** Defining radiation induced liver toxicity in the treatment of hepatocellular carcinoma: Which metric is most predictive for survival? (Abstract 361)
First Author: Tobias Robert Chapman
- BOARD H21:** Impact of radiation and surgery for intraductal papillary neoplasm of the bile duct: A population-based analysis. (Abstract 363)
First Author: Sean Szeja
- BOARD H20:** Comparative analysis of resected duodenal and ampullary adenocarcinoma. (Abstract 362)
First Author: Angelena Crown

POSTER SESSION B, *continued*

- BOARD H22:** Optimal prognostic lymph node staging system for gallbladder adenocarcinoma: A multi-institutional study. (Abstract 364)
First Author: Neda Amini
- BOARD J1:** Impact of preoperative chemotherapy on overall survival for borderline resectable colorectal liver metastases. (Abstract 365)
First Author: Akio Saiura
- BOARD J2:** Using the ALBI grade as a prognostic marker for radioembolization of hepatocellular carcinoma. (Abstract 366)
First Author: Homan Mohammadi
- BOARD J3:** Survival impact of neoadjuvant therapy in resected pancreatic cancer. (Abstract 367)
First Author: Katelin Anne Mirkin
- BOARD J4:** Effect of time to initiation of adjuvant chemotherapy on survival in resected pancreatic cancer. (Abstract 368)
First Author: Katelin Anne Mirkin
- BOARD J5:** Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC). (Abstract 369)
First Author: Nai-Jung Chiang
- BOARD J6:** Role of adjuvant chemoradiotherapy for duodenal cancer: An update of the experience at a single institution. (Abstract 370)
First Author: Hae Jin Park
- BOARD J7:** A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma. (Abstract 371)
First Author: Teresa Macarulla
- BOARD J8:** Clinical outcomes of resectable small bowel adenocarcinoma treated by surgery alone: Case series in a Japanese single institution. (Abstract 372)
First Author: Shoko Noda
- BOARD J9:** Importance of subset classification based on tumor size for patients with single hepatocellular carcinoma. (Abstract 373)
First Author: Jian-Hong Zhong
- BOARD J11:** Knowledge-based planning for stereotactic body radiation therapy (SBRT) of the liver. (Abstract 375)
First Author: Hunter C. Gits
- BOARD J12:** A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC). (Abstract 376)
First Author: Theodore S. Hong

- BOARD J14:** Impact of concurrent medications use on outcome of pancreatic cancer: SEER Medicare analysis. (Abstract 378)
First Author: Muhammad Shaalan Beg
- BOARD J15:** Radiotherapy for intrahepatic cholangiocarcinoma: An analysis of the National Cancer Database. (Abstract 379)
First Author: Abdulrahman Y. Hammad
- BOARD J16:** Risks of thromboembolic events among patients diagnosed with metastatic pancreatic ductal adenocarcinoma treated with chemotherapy. (Abstract 380)
First Author: Bela Bapat
- BOARD J17:** Towards an absolute bilirubin threshold for preoperative biliary decompression in patients undergoing whipple. (Abstract 381)
First Author: Catalina Mosquera
- BOARD J18:** Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies. (Abstract 382)
First Author: Mairead G. McNamara
- BOARD J19:** Effect of metformin on survival in pancreatic ductal adenocarcinoma. (Abstract 383)
First Author: Sunil Amin
- BOARD J20:** Multidisciplinary management of pancreatic adenocarcinoma with isolated pulmonary metastases. (Abstract 384)
First Author: Supriya K. Jain
- BOARD K1:** A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma. (Abstract 385)
First Author: Beate Schultheis
- BOARD K2:** Nutritional status and outcomes of older versus younger patients (pts) with metastatic pancreatic cancer (mPC). (Abstract 386)
First Author: Namrata Vijayvergia
- BOARD K3:** Impact of chemotherapy and external beam radiation therapy on outcomes among patients with resected gallbladder cancer: A multi-institutional analysis. (Abstract 387)
First Author: Yuhree Kim
- BOARD K4:** Curative resection for hilar cholangiocarcinoma: Does adjuvant therapy impact overall survival? A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium. (Abstract 388)
First Author: Bradley Krasnick
- BOARD K5:** Novel nomogram combining depth of invasion and size to predict the benefit of regional lymphadenectomy for appendiceal neuroendocrine tumors (A-NET). (Abstract 389)
First Author: Catalina Mosquera

POSTER SESSION B, *continued*

- BOARD K6:** Palliative care for hepatocellular carcinoma: Analysis of the National Cancer Data Base. (Abstract 390)
First Author: Abdulrahman Y. Hammad
- BOARD K7:** Long-term responders to palliative chemotherapy for advanced biliary tract cancer. (Abstract 391)
First Author: Mark Doherty
- BOARD K8:** Treatment strategy for intrahepatic cholangiocarcinoma: From optimal surgical management to adjuvant therapy. (Abstract 392)
First Author: Yuji Morine
- BOARD K9:** Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC). (Abstract 393)
First Author: Florence K. Keane
- BOARD K10:** Intention to treat analysis of neoadjuvant chemoradiation and liver transplantation for perihilar cholangiocarcinoma. (Abstract 394)
First Author: Benjamin Loveday
- BOARD K11:** Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. (Abstract 395)
First Author: Stacey Stein
- BOARD K12:** Splenic embolization as an alternative to surgical splenectomy for the restoration of blood counts suitable for effective chemotherapy in gastrointestinal malignancies (GIM). (Abstract 396)
First Author: Robert de Wilton Marsh
- BOARD K13:** Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG). (Abstract 397)
First Author: Shannon Leah Schmidt
- BOARD K14:** Outcomes of neoadjuvant chemotherapy versus chemoradiation among patients with resected pancreatic head adenocarcinoma. (Abstract 398)
First Author: Jan Franko
- BOARD K15:** FOLFIRINOX and gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced unresectable pancreatic adenocarcinoma. (Abstract 399)
First Author: Filip Bednar
- BOARD K16:** Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial. (Abstract 400)
First Author: Susan Tsai

- BOARD K17:** Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. (Abstract 401)
First Author: Maria M. Zlobinsky Rubinstein
- BOARD K18:** The minimal effective relative dose intensity (RDI) for modified FOLFIRINOX in advanced pancreatic cancer: Suggestion for modified Hryniuk's calculation method. (Abstract 402)
First Author: Jong-chan Lee
- BOARD K19:** Radiological markers of treatment responsiveness in patients (pts) with metastatic pancreatic ductal adenocarcinomas (mPDAC) receiving systemic chemotherapy. (Abstract 403)
First Author: Peter Yong Soo Park
- BOARD K20:** Tolerability and clinical outcomes in elderly patients with advanced pancreatic cancer treated with FOLFIRINOX. (Abstract 404)
First Author: Taikan Yamamoto
- BOARD K22:** Neoadjuvant chemotherapy for gall bladder cancer: Does it increase resectability? (Abstract 406)
First Author: Dheeraj Raj
- BOARD L1:** JASPAC 06: Observational study of FOLFIRINOX therapy for unresectable and recurrent pancreatic cancer—Preliminary report on serious adverse events. (Abstract 407)
First Author: Masato Ozaka
- BOARD L2:** FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study. (Abstract 408)
First Author: Jon Kroll Bjerregaard
- BOARD L4:** Local effect and gastrointestinal toxicity for carbon-ion radiotherapy in patients with unresectable locally advanced pancreatic cancer. (Abstract 410)
First Author: Makoto Shinoto
- BOARD L5:** Prediction of metastatic pancreatic cancer patients' survival using both host immunity and tumor metabolic activity. (Abstract 411)
First Author: Younak Choi
- BOARD L6:** Perioperative outcomes following composite resections for colorectal cancer with liver metastases: Can we do better? (Abstract 412)
First Author: Jane Yuet Ching Hui
- BOARD L7:** Impact of stereotactic body radiation therapy on patient-reported quality of life in patients with unresectable or recurrent pancreatic cancer. (Abstract 413)
First Author: Lauren M. Rosati

POSTER SESSION B, *continued*

- BOARD L8:** Viral hepatitis associated hepatocellular carcinoma outcomes with Y-90 radioembolization. (Abstract 414)
First Author: Jessica M. Frakes
- BOARD L9:** The association between sarcopenia and treatment outcomes in patients with pancreatic cancer undergoing chemoradiation. (Abstract 415)
First Author: Kajal Patel
- BOARD L10:** Natural history of T1N0M0 hepatocellular carcinoma: Large scale study in the United States. (Abstract 416)
First Author: Humaid Obaid Al-Shamsi
- BOARD L11:** Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. (Abstract 417)
First Author: Andrea Wang-Gillam
- BOARD L12:** The use of stereotactic body radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. (Abstract 418)
First Author: Aisling S. Barry
- BOARD L13:** RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (P) in patients (pts) with metastatic pancreatic cancer (mPC). (Abstract 419)
First Author: Andrew H. Ko
- BOARD L14:** Prognostic effect of angiotensin-converting-enzyme inhibitors (ACEI) and diuretics in patients with pancreatic cancer. (Abstract 420)
First Author: Humaid Obaid Al-Shamsi
- BOARD L15:** Trends in treatment and survival for advanced pancreatic cancer: Progress or progression? (Abstract 421)
First Author: Mariam F. Eskander
- BOARD L16:** Safety and efficacy of dose-modified FOLFIRINOX on toxicity and effectiveness in Japanese patients with unresectable pancreatic cancer (PC). (Abstract 422)
First Author: Kazuhiro Uesugi
- BOARD L17:** Association of decreased peak SUV on PET after neoadjuvant therapy in patients with borderline resectable pancreatic carcinoma with pathologic response. (Abstract 423)
First Author: Evan Scott Glazer
- BOARD L18:** Phase II study of individualized adaptive stereotactic body radiotherapy (SBRT) for patients at high risk for liver damage. (Abstract 424)
First Author: Mary Uan-Sian Feng

- BOARD L19:** Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. (Abstract 425)
First Author: Li-Tzong Chen
- BOARD L20:** Multidisciplinary approach to patients with recurrent colorectal liver metastases. (Abstract 426)
First Author: Luca Vigano
- BOARD L21:** Influence of pre-diagnosis statin use on survival among patients with pancreatic cancer. (Abstract 427)
First Author: Brian Z. Huang
- BOARD L22:** Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)? (Abstract 428)
First Author: Shannon Leah Schmidt
- BOARD M1:** Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P+G) versus gemcitabine monotherapy (G) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a U.S. community oncology setting. (Abstract 429)
First Author: Fadi S. Braiteh
- BOARD M2:** Nab-paclitaxel plus gemcitabine followed by radiotherapy with concurrent 5-FU in locally advanced unresectable pancreatic cancer: A Western Australian experience. (Abstract 430)
First Author: Andrew Peter Dean
- BOARD M4:** EUS combined with CT in predicting SMV/PV resection in patients with borderline resectable pancreatic carcinoma. (Abstract 432)
First Author: Evan Scott Glazer
- BOARD M5:** Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P+G) versus FOLFIRINOX (FFX) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a U.S. community oncology setting. (Abstract 433)
First Author: Fadi S. Braiteh
- BOARD M6:** Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (Abstract 434)
First Author: Alexandria T. Phan
- BOARD M7:** The effect of postoperative morbidity on long-term survival after curative resection for extra-hepatic biliary tumors: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium. (Abstract 435)
First Author: Linda Jin

POSTER SESSION B, *continued*

- BOARD M8:** Retrospective phase II study of efficacy and safety of 177Lu-DOTATOC peptide receptor radiotherapy in patients with advanced neuroendocrine tumours. (Abstract 436)
First Author: Richard P. Baum
- BOARD M9:** Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis. (Abstract 437)
First Author: Maeve Aine Lowery
- BOARD M10:** Outcome analysis of primary liver carcinomas. (Abstract 438)
First Author: Maria Majella Doyle
- BOARD M11:** Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer. (Abstract 439)
First Author: Sunil R. Hingorani
- BOARD M12:** The impact of modified Glasgow Prognostic Scale as a predictor of survival advantage by FOLFIRINOX in metastatic pancreatic cancer. (Abstract 440)
First Author: Ikuhiro Yamada
- BOARD M13:** Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers. (Abstract 441)
First Author: Ulrich-Frank Pape
- BOARD M14:** Diverse clinical outcome and predictors for clinical outcome in patients with HCC treated with TACE. (Abstract 442)
First Author: Prarthna Bhardwaj
- BOARD M15:** Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)? (Abstract 443)
First Author: Shinoj Pattali Jayavalsan
- BOARD M16:** A matched pair analysis of five-fraction stereotactic body radiation therapy versus protracted conventional radiation therapy in patients receiving chemotherapy for locally advanced pancreatic cancer. (Abstract 444)
First Author: Antony Koroulakis
- BOARD M17:** Two-arc volumetric modulated arc therapy to provide dosimetric advantages for pancreas stereotactic body radiotherapy. (Abstract 445)
First Author: Jason K. Molitoris
- BOARD M18:** Perioperative calculator to predict complications for patients with hepatocellular carcinoma resection. (Abstract 446)
First Author: Katherine Ostapoff

- BOARD M19:** Perioperative management of pancreatoduodenectomy patients: Are North American practices any different? A survey involving IHPBA/AHPBA members. (Abstract 447)
First Author: Sandeep Anantha
- BOARD M20:** Variations in the perioperative management of pancreatoduodenectomy between academic and community institutions: An IHPBA/AHPBA web-based survey. (Abstract 448)
First Author: Sandeep Anantha
- BOARD M21:** Are practice patterns of high-volume pancreatic surgeons distinct from low-volume pancreatic surgeons? A IHPBA/AHPBA web-based survey study. (Abstract 449)
First Author: Fransisco Igor Macedo
- BOARD M22:** Carcinoid syndrome-related symptoms in pancreatic neuroendocrine tumors (pNETs) and impact on health care utilization. (Abstract 450)
First Author: Michael S. Broder
- BOARD N1:** Treatment of borderline resectable (BR) and locally advanced (LA) pancreatic cancer in the era of FOLFIRINOX and gemcitabine plus nab-paclitaxel: A multi-institutional study. (Abstract 451)
First Author: Kamran Idrees
- BOARD N2:** Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer. (Abstract 452)
First Author: Nathan Bahary
- BOARD N3:** Predictors and survival for pathologic tumor response grade (TRG) in borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy (SBRT). (Abstract 453)
First Author: Eric Albert Mellon
- BOARD N4:** A prospective study evaluating stereotactic body radiation therapy in unresectable, recurrent, or residual pancreatic adenocarcinoma. (Abstract 454)
First Author: Lauren M. Rosati
- BOARD N5:** Conditional probability of survival in gallbladder carcinoma as a prognostic tool for long term survivors. (Abstract 455)
First Author: Rahul Rajeev
- BOARD N6:** Palliative treatment in extrahepatic biliary malignancies: A multi-institutional cohort. (Abstract 456)
First Author: Ana Wilson
- BOARD N7:** Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC). (Abstract 457)
First Author: Vincent J. Picozzi

- BOARD N8:** Effect of transarterial chemoembolization prior to selective internal radiation therapy on yttrium-90 microsphere delivery in hepatocellular carcinoma patients. (Abstract 458)
First Author: Mu-Han Lin
- BOARD N9:** Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer. (Abstract 459)
First Author: Dung T. Le
- BOARD N10:** Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin. (Abstract 460)
First Author: Hyun S. Kim
- BOARD N11:** The impact of the multiple types of treatments on OS and the decline of liver function in patients with advanced stage of HCC. (Abstract 461)
First Author: Petra Prins
- BOARD N12:** Accuracy of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting node positivity and metastatic disease in patients with gastrointestinal malignancies. (Abstract 462)
First Author: Matthew Doepker
- BOARD N13:** Use of radiofrequency ablation and stereotactic body radiotherapy for the treatment of hepatocellular carcinoma: An analysis of the SEER-Medicare database. (Abstract 463)
First Author: Mary Uan-Sian Feng

12:00 PM–2:00 PM and 5:30 PM–7:00 PM

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

LEVEL 1, WEST HALL

Posters by Topic

Prevention, Diagnosis, and Screening: *Poster Board N14*

Multidisciplinary Treatment: *Poster Boards N15–N22*

Translational Research: *Poster Boards O1–O15*

- BOARD N14:** Cell-free DNA genotyping using digital PCR for early detection of pancreatic neoplasm. (Abstract TPS464)
First Author: Hidenori Karasaki
- BOARD N15:** Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. (Abstract TPS465)
First Author: Zev A. Wainberg
- BOARD N16:** A phase I study of veliparib (ABT-888) in combination with capecitabine (C) and temozolomide (T) in patients (pts) with advanced well-differentiated unresectable neuroendocrine tumors (wdNET). (Abstract TPS466)
First Author: Ramya Thota
- BOARD N17:** A phase I trial with cohort expansion of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer. (Abstract TPS467)
First Author: Heloisa P. Soares
- BOARD N18:** Multi-institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers. (Abstract TPS468)
First Author: Heloisa P. Soares
- BOARD N19:** A phase Ia/Ib trial of trametinib in combination with sorafenib in patients with advanced hepatocellular cancer. (Abstract TPS469)
First Author: Heloisa P. Soares
- BOARD N20:** A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer. (Abstract TPS470)
First Author: Austin G. Duffy
- BOARD N21:** A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma. (Abstract TPS471)
First Author: Andrea S. Teague
- BOARD N22:** Phase I dose escalation and pharmacokinetic study of a modified schedule of 14-o-phosphonoxyethyltriptolide. (Abstract TPS472)
First Author: Edward Greeno

TRIALS IN PROGRESS POSTER SESSION B, *continued*

- BOARD 01:** AFACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC). (Abstract TPS473)
First Author: Margaret A. Tempero
- BOARD 02:** A phase I safety and pharmacokinetic (PK) study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients (pts) with advanced pancreatic cancer (APC) who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction. (Abstract TPS474)
First Author: Hanno Riess
- BOARD 03:** nab-paclitaxel (nab-P) + nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC). (Abstract TPS475)
First Author: Irfan Firdaus
- BOARD 04:** Perioperative stromal depletion by PEGPH20 in pancreatic ductal adenocarcinoma. (Abstract TPS476)
First Author: Andrew H. Ko
- BOARD 05:** LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC). (Abstract TPS477)
First Author: Philip Agop Philip
- BOARD 06:** A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2). (Abstract TPS478)
First Author: Andrew X. Zhu
- BOARD 07:** A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial. (Abstract TPS479)
First Author: Enrique Grande
- BOARD 08:** Prospective phase I study of nab-paclitaxel plus gemcitabine with concurrent MR-guided IMRT in patients with locally advanced or borderline resectable pancreatic cancer. (Abstract TPS480)
First Author: Jeffrey R. Olsen
- BOARD 09:** A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC). (Abstract TPS481)
First Author: Andrew H. Ko

- BOARD O10:** A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC). (Abstract TPS482)
First Author: Andrew Dean
- BOARD O11:** A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE). (Abstract TPS483)
First Author: Margaret A. Tempero
- BOARD O12:** Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study. (Abstract TPS484)
First Author: Erkut Hassan Borazanci
- BOARD O13:** Cisplatin plus irinotecan in the treatment of gallbladder or biliary tract cancer: A randomized phase II trial (NCT01859728). (Abstract TPS485)
First Author: Lucas Vieira dos Santos
- BOARD O14:** Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). (Abstract TPS486)
First Author: Dung T. Le
- BOARD O15:** Phase I study of veliparib with gemcitabine and radiation therapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer. (Abstract TPS487)
First Author: Richard Tuli

7:00 AM–7:55 AM and 12:30 PM–2:00 PM

Poster Session C: Cancers of the Colon, Rectum, and Anus

LEVEL 1, WEST HALL

Posters by Topic

Prevention, Diagnosis, and Screening: *Poster Boards A1, A4, A8–D1*

Multidisciplinary Treatment: *Poster Boards A2–A3, A5–A6, G15–O2*

Translational Research: *Poster Boards A7, D2–G14*

- BOARD A1:** Early detection of colorectal neoplasia: Combination of eight cancer-associated blood-based protein biomarkers. (Abstract 488)
First Author: Ib J. Christensen
- BOARD A2:** Neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer: Results of a Polish II multicentre phase III study. (Abstract 489)
First Author: Krzysztof Bujko
- BOARD A3:** ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up. (Abstract 490)
First Author: Eric Francois
- BOARD A4:** The incidence of secondary pelvic tumors after previous (chemo)radiation for rectal cancer. (Abstract 491)
First Author: Anouk J.M. Rombouts
- BOARD A5:** Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). (Abstract 492)
First Author: Johanna C. Bendell
- BOARD A6:** MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs. FOLFIRI-BV with biomarker stratification in patients (pts) with metastatic colorectal cancer (mCRC). (Abstract 493)
First Author: Heinz-Josef Lenz
- BOARD A8:** A novel 2-gene blood test for colorectal cancer recurrence. (Abstract 495)
First Author: Susanne Kartin Pedersen
- BOARD A9:** Outcomes of perioperative systemic therapy (ST) in patients with R0 resection of metastatic colorectal cancer (mCRC). (Abstract 496)
First Author: Richard M. Lee-Ying
- BOARD A10:** Comprehensive genomic profiling of advanced colorectal carcinoma in the course of clinical care to identify KRAS insertions not detected by focused molecular testing. (Abstract 497)
First Author: Andrew Rankin

- BOARD A11:** Association of TLR9 polymorphism with overall survival in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab enrolled in FIRE3. (Abstract 498)
First Author: Satoshi Okazaki
- BOARD A13:** A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial results. (Abstract 500)
First Author: Richard D. Kim
- BOARD A14:** Patterns of recurrence by microsatellite instability in colorectal cancer. (Abstract 501)
First Author: Chang-gon Kim
- BOARD A15:** Perioperative chemotherapy using FOLFOX with panitumumab for locally advanced rectal cancer: Phase II trial. (Abstract 502)
First Author: Mitsuyoshi Ota
- BOARD A16:** Changes in apparent diffusion coefficient evaluated with diffusion-weighted MRI to predict complete pathologic response after neoadjuvant therapy for rectal cancer: Literature review and meta-analysis. (Abstract 503)
First Author: Vincenzo Desiato
- BOARD A17:** Assessing solid tumor response with and without RECIST. (Abstract 504)
First Author: Aileen Deng
- BOARD A18:** Molecular characterization of colorectal tumors in young patients compared with older patients and impact on outcome. (Abstract 505)
First Author: Arielle Celeste Heeke
- BOARD A19:** Small RNA sequencing of colorectal cancer to reveal differences in microRNA expression between normal and tumor tissue. (Abstract 506)
First Author: Robin Mjelle
- BOARD A20:** Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). (Abstract 507)
First Author: Marc Peeters
- BOARD A21:** To screen or not to screen: Colonoscopy, a story of successful population-based screening. (Abstract 508)
First Author: Catalina Mosquera
- BOARD A22:** The FAMKOL trial: Trans-sectoral screening in high-risk populations, comparing nurse-led counselling versus written information materials in first-degree relatives of patients with colorectal cancer. (Abstract 509)
First Author: Alexander Bauer

GENERAL POSTER SESSION C, *continued*

- BOARD B1:** Comparison of a large NGS panel to hot-spot testing and small panels for the ability to accurately stratify advanced colorectal cancer patients to appropriate treatment pathways. (Abstract 510)
First Author: Stephen Lyle
- BOARD B2:** Objective sleep duration (SD) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC). (Abstract 511)
First Author: David Spiegel
- BOARD B3:** Prevalence of metabolic syndrome in older (50 years and older) vs younger (less than 50 years) patients with colorectal cancer diagnosed in a safety net hospital system. (Abstract 512)
First Author: Ashish Sharma
- BOARD B4:** RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data. (Abstract 513)
First Author: George Kafatos
- BOARD B5:** Is the accuracy of preoperative MRI stage in rectal carcinoma influenced by tumor height? (Abstract 514)
First Author: Laurids Østergaard Poulsen
- BOARD B6:** Changes in non-invasive liver fibrosis indices during chemotherapy: Potential marker for oxaliplatin-induced sinusoidal obstruction syndrome. (Abstract 515)
First Author: Jin-Soo Kim
- BOARD B7:** Verification of T-plus staging system for colorectal cancer based on nomogram analysis of single center's 25-year follow-up. (Abstract 516)
First Author: Ke-Feng Ding
- BOARD B8:** Prevalence of colorectal adenoma in patients with multiple gastric adenoma or cancers. (Abstract 517)
First Author: Jung Wan Choe
- BOARD B9:** Epidemiology and survival of small cell carcinoma of gastrointestinal tract: A Surveillance, Epidemiology, and End Results (SEER) database review. (Abstract 518)
First Author: Abhijeet Kumar
- BOARD B10:** Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT. (Abstract 519)
First Author: Marc Peeters
- BOARD B11:** Racial and sex disparities in changing trends of squamous cell cancer of the anus (SSCA). (Abstract 520)
First Author: Arjun Gupta

- BOARD B12:** Germline pharmacogenomics in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. (Abstract 521)
First Author: Moh'd M. Khushman
- BOARD B13:** Updated analysis: Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802)—Sub-group analysis by KRAS Exon2 status. (Abstract 522)
First Author: Michio Nakamura
- BOARD B14:** Prospective observational study for the impact of short-term periodic intravenous steroid premedication for gastrointestinal cancer chemotherapy on bone metabolism. (Abstract 523)
First Author: Atsushi Ishiguro
- BOARD B15:** Assessing distress in patients with gastrointestinal tumors during radiotherapy. (Abstract 524)
First Author: Laeticia Hollant
- BOARD B16:** The quality of CT surveillance in resected colorectal cancer survivors at Veterans Health Administration facilities. (Abstract 525)
First Author: Amikar Sehdev
- BOARD B17:** Postcolonoscopy colorectal cancers in average-risk Korean subjects with a normal initial colonoscopy. (Abstract 526)
First Author: Han Hee Lee
- BOARD B18:** How often does the patient repeat screening colonoscopy? A study for personalized recommendation of screening colonoscopy interval. (Abstract 527)
First Author: Eun Sun Kim
- BOARD B19:** Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP). (Abstract 528)
First Author: Michael J. Hall
- BOARD B20:** The novel diagnostic method for colorectal cancer: Detection of methyl mercaptan from flatus. (Abstract 529)
First Author: Atsushi Ishibe
- BOARD B21:** RAS testing awareness amongst oncologists and panitumumab prescription for metastatic colorectal cancer: A European physician survey and medical records review. (Abstract 530)
First Author: Jorg Trojan
- BOARD B22:** Impact of infectious complications on long-term survival following colorectal cancer surgery. (Abstract 531)
First Author: Ali Mokdad
- BOARD C1:** Lynch Syndrome diagnosis in Ireland: The impact of universal mismatch repair protein testing. (Abstract 532)
First Author: Lynda Corrigan

GENERAL POSTER SESSION C, *continued*

- BOARD C2:** Rate of implementation of universal testing for Lynch Syndrome in a county hospital system. (Abstract 533)
First Author: Ashish Sharma
- BOARD C3:** Predictors of recurrence in stage I/II colorectal cancer: Analysis of a single institution's experience for over 24 years. (Abstract 534)
First Author: Miguel Gonzalez Velez
- BOARD C4:** Genotype-phenotype correlation of gastric cancer in familial adenomatous polyposis. (Abstract 535)
First Author: Tatsuhiro Ito
- BOARD C5:** Tumor marker CA 11-19 as a new serum blood test for monitoring colorectal cancer. (Abstract 536)
First Author: John J. Costanzi
- BOARD C6:** Defective mismatch repair (dMMR) status as a predictive biomarker in Chinese patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) + chemotherapy. (Abstract 537)
First Author: Jiayu Ling
- BOARD C7:** Tumor genomic profiling (TGP) in metastatic colorectal cancer (CRC): Bridging the community and the tertiary cancer center through genomic consultation (GC). (Abstract 538)
First Author: John M. Kaczmar
- BOARD C8:** Expression of P4H9-detecting molecule on spindle-shaped fibroblasts to indicate malignant phenotype of colorectal cancer. (Abstract 539)
First Author: Shozo Yokoyama
- BOARD C9:** Thrombocytosis as a predictor of poor prognosis in colorectal cancer patients. (Abstract 540)
First Author: Ravi Ramjeesingh
- BOARD C10:** Thromboembolism incidence in patients with gastrointestinal tract cancer receiving chemotherapy: A single-institutional retrospective cohort analysis. (Abstract 541)
First Author: Ayane Oba
- BOARD C11:** RAS mutational status and CEA production at initial presentation in metastatic colorectal cancer. (Abstract 542)
First Author: May Thet Cho
- BOARD C12:** Methylated BCAT1 and IKZF1 DNA in tissue and plasma from colorectal cancer cases. (Abstract 543)
First Author: Erin L. Symonds

- BOARD C13:** Novel solution to achieve “80% by 2018” Two-Man colonoscopy performed by primary care physicians with expert back-up: Compliance and capacity without diluting quality. (Abstract 544)
First Author: Stephen Carroll Lloyd
- BOARD C14:** Early-onset small bowel and colorectal cancer patients with BRCA mutations: Actionable variants in atypical presentations. (Abstract 545)
First Author: Karen Vikstrom
- BOARD C15:** Molecular profiling of TOPO1: A way to evaluate irinotecan treatment in colorectal cancer? (Abstract 546)
First Author: Julia Marie Cunningham
- BOARD C16:** Sensitive, specific and modular KRAS, NRAS, and BRAF assays for simultaneous detection of 30 important point mutations in colorectal cancer specimens. (Abstract 547)
First Author: Kiran Madanahally Divakar
- BOARD C17:** IHC-based predictive biomarker for irinotecan response. (Abstract 548)
First Author: Koji Ando
- BOARD C18:** The prevalence of colorectal polyps in patients with gastric cancer. (Abstract 549)
First Author: Kyoung-Joo Kwon
- BOARD C19:** Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens. (Abstract 550)
First Author: Arthur C. Houts
- BOARD C20:** KRAS testing disparities in the state of New Mexico. (Abstract 551)
First Author: Alissa Greenbaum
- BOARD D1:** Disease control and survival outcomes for rectal adenocarcinoma (RA) managed with neoadjuvant chemoradiotherapy (nCRT): Performance of serum CEA changes as a biomarker. (Abstract 552)
First Author: Tangel Chang
- BOARD D2:** Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study. (Abstract 553)
First Author: Jean-François Emile
- BOARD D3:** Differential radiographic appearance of BRAF V600E mutant metastatic colorectal cancer (mCRC) in patients matched by primary tumor location. (Abstract 554)
First Author: Claire Greene
- BOARD D4:** Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer. (Abstract 555)
First Author: Anita Sveen

GENERAL POSTER SESSION C, *continued*

- BOARD D5:** Genomic features of primary and recurrent anal squamous cell carcinoma. (Abstract 556)
First Author: Jonathan W. Pike
- BOARD D6:** Novel driver genes and genomic predictors of immune infiltrates in colorectal cancer. (Abstract 557)
First Author: Marios Giannakis
- BOARD D7:** Association between cetuximab response and differential immunologic gene expression signatures in colorectal cancer metastases. (Abstract 558)
First Author: Michael Sangmin Lee
- BOARD D8:** Effect of age and ethnicity on the tumor location, nuclear accumulation of p53 and clinical outcome in colorectal adenocarcinoma. (Abstract 559)
First Author: Ravi Kumar Paluri
- BOARD D9:** A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer. (Abstract 560)
First Author: Austin G. Duffy
- BOARD D10:** Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer. (Abstract 265)
First Author: Van Karlyle Morris
- BOARD D11:** Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study. (Abstract 562)
First Author: Sebastian Stintzing
- BOARD D12:** Clusterin expression (CLU) as a prognostic marker in colorectal carcinoma (CCR). (Abstract 563)
First Author: Julia Alcaide
- BOARD D13:** Clinical prognostic factors and genomic analysis of ovary metastases (mets) from colorectal cancer (CRC). (Abstract 564)
First Author: Karuna Ganesh
- BOARD D14:** Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. (Abstract 565)
First Author: Amir Mehrvarz Sarshekeh
- BOARD D15:** Micro-RNAs in stage II colorectal cancer: Is there any role? (Abstract 566)
First Author: Salem Eid Mohamed
- BOARD D16:** BRAF mutations in patients with large cell neuroendocrine carcinoma of the colon (LCNECC). (Abstract 567)
First Author: Karuna Ganesh

- BOARD D17:** Clinical and molecular assessment of response to regorafenib. (Abstract 568)
First Author: Nao Kakizawa
- BOARD D18:** Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC). (Abstract 569)
First Author: Joleen Marie Hubbard
- BOARD D19:** Comprehensive genomic profiling in colorectal cancer (CRC) to identify differing frequencies of clinically relevant genomic alterations (CRGA) in tumors of patients (pts) less than age 50 as compared to those of pts over age 65. (Abstract 570)
First Author: Mark Bailey
- BOARD D20:** Molecular profiling of appendix-derived pseudomyxoma peritonei (PMP). (Abstract 571)
First Author: Elizabeth Gleeson
- BOARD D21:** Possible role of the systemic inflammatory reaction in defining tumor responder vs. nonresponder in cancer macrobead therapy. (Abstract 572)
First Author: Barry H. Smith
- BOARD D22:** Post-treatment surveillance in locally advanced squamous cell carcinoma (SCCA) of the anal canal: A global subspecialist survey. (Abstract 573)
First Author: Cathy Eng
- BOARD E1:** Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma. (Abstract 574)
First Author: Maria Ignez Freitas Melro Braghiroli
- BOARD E2:** The prognostic role of the host immune response in rectal cancer patients treated with neoadjuvant chemoradiation. (Abstract 575)
First Author: Thilo Sprenger
- BOARD E4:** Interaction of KRAS somatic mutation and colorectal carcinoma and its association with differential DNA methylation. (Abstract 577)
First Author: Farzana Jasmine
- BOARD E5:** Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC). (Abstract 578)
First Author: Ignacio Matos
- BOARD E6:** Whether mCRC patients with other RAS mutations benefit from the addition of bevacizumab as first-line therapy. (Abstract 579)
First Author: Mingyi Zhou
- BOARD E7:** A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result. (Abstract 580)
First Author: Khurum Hayat Khan

GENERAL POSTER SESSION C, *continued*

- BOARD E8:** Novel probe-based quantitative image of mitochondria in live colon cancer tissues by multiphoton microscopy. (Abstract 581)
First Author: Eun Sun Kim
- BOARD E9:** Levels of oxidative stress and telomeres in Lynch syndrome-associated malignancies. (Abstract 582)
First Author: Grainne O’Kane
- BOARD E10:** Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)]. (Abstract 583)
First Author: Juan Maurel
- BOARD E11:** Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience. (Abstract 584)
First Author: Kristin Lynn Koenig
- BOARD E12:** Tumor site, clinicopathological characteristics, and survival of patients undergoing primary elective colorectal cancer resection. (Abstract 585)
First Author: James Hugh Park
- BOARD E13:** Serum amyloid α (SAA-1) SNP rs12218 to predict outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. (Abstract 586)
First Author: Martin D. Berger
- BOARD E14:** Prognostic impact of tumor-associated B cells and plasma cells in colorectal cancer. (Abstract 587)
First Author: Jonna Berntsson
- BOARD E15:** Predictive value of ERCC1 and KRAS in colorectal cancer patients with FOLFOX chemotherapy. (Abstract 588)
First Author: In Kyu Lee
- BOARD E16:** Alteration of ADCC-related genes as a novel predictor of efficacy of cetuximab (cet)-based chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC) (JACCRO CC-05/06 AR). (Abstract 589)
First Author: Yu Sunakawa
- BOARD E17:** Assessing intratumor heterogeneity and evolutionary distance in exome sequencing of colon cancer. (Abstract 590)
First Author: Ulrich Popper
- BOARD E18:** Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients. (Abstract 591)
First Author: Benny C. Johnson

- BOARD E19:** Effect of 5-fluorouracil on membranous PD-L1 expression in colon cancer cells. (Abstract 592)
First Author: Gaurav Goel
- BOARD E20:** The lymphocyte-to-monocyte ratio as a predictor of overall survival in comparison to established systemic markers of inflammation in resectable colorectal cancer. (Abstract 593)
First Author: Joseph Chan
- BOARD E21:** Long-term effect of Wnt/ β -catenin small molecule inhibitor CWP232291 on intestinal carcinogenesis in novel GEM model deficient in Smad4 and p53. (Abstract 594)
First Author: Jun Won Park
- BOARD E22:** Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennaryN-glycan as a novel tumor marker for colorectal cancer. (Abstract 595)
First Author: Eiji Shinozaki
- BOARD F1:** Does pre-operative aspirin and statin prescription modulate the post-operative systemic inflammatory response following surgery for colorectal cancer? (Abstract 596)
First Author: David G. Watt
- BOARD F2:** Post-operative C-reactive protein concentration: A potential therapeutic target following surgery for colorectal cancer? (Abstract 597)
First Author: David G. Watt
- BOARD F3:** The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer. (Abstract 598)
First Author: Tamer Garawin
- BOARD F5:** The occurrence of mutant KRAS clones in the blood of RAS wild type colorectal cancer patients: Impact of response or failure under anti-EGFR therapy. (Abstract 600)
First Author: Andreas W. Berger
- BOARD F6:** Oxaliplatin associated neurotoxicity outcomes among older adults with colorectal cancer: A population-based study. (Abstract 601)
First Author: Michael J. Raphael
- BOARD F7:** Liquid biopsy leads to a paradigm shift in cancer treatment. (Abstract 602)
First Author: Koichi Suzuki
- BOARD F8:** Perioperative chemotherapy with S-1 plus oxaliplatin (SOX) for stage III colorectal cancer patients. (Abstract 603)
First Author: Naoya Aisu
- BOARD F9:** Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines. (Abstract 604)
First Author: Peter Eide

GENERAL POSTER SESSION C, *continued*

- BOARD F10:** Emerging transcriptional landscape and putative therapeutic targets in young patients with metastatic colorectal cancer (CRC). (Abstract 605)
First Author: Christopher Hanyoung Lieu
- BOARD F11:** Signal transduction and activator of transcription 3 (STAT3), host inflammatory responses and survival of patients with colorectal cancer. (Abstract 606)
First Author: James Hugh Park
- BOARD F12:** Limits on costs and values of anticancer drugs in metastatic colorectal cancer: Policies and proposal. (Abstract 607)
First Author: Helmy M. Guirgis
- BOARD F13:** Trifluridine to enhance cytotoxicity by DNA mismatch repair deficiency and subsequent MBD4 frameshift mutation in colorectal cancer. (Abstract 608)
First Author: Satoshi Suzuki
- BOARD F14:** Histological tumor regression after preoperative chemotherapy for colorectal liver metastases: Correlations with radiological response and prognosis. (Abstract 609)
First Author: Ryo Inada
- BOARD F15:** A pooled analysis of the secondary resection for colorectal cancer liver metastases: Comparison of bevacizumab (Bmab) and anti-EGFRs. (Abstract 610)
First Author: Wataru Ichikawa
- BOARD F16:** Prognostic significance of programmed death-ligand 1 (PD-L1) expression on tumor infiltrating immune cells (IC) in patients with stage IIIb colorectal cancer. (Abstract 611)
First Author: Shigehiro Koganemaru
- BOARD F17:** BRAF mutations in colonic high-grade neuroendocrine carcinoma. (Abstract 612)
First Author: Chandrasekhar Padmanabhan
- BOARD F18:** Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatin-based chemotherapy: A subgroup analysis of the JACCRO CC-05/06. (Abstract 613)
First Author: Yu Sunakawa
- BOARD F19:** Methylation profiling of locally advanced rectal cancer (LARC): Exploration of potential predictive markers for neoadjuvant chemoradiation (NACR). (Abstract 614)
First Author: Songchuan Guo
- BOARD F20:** Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer. (Abstract 615)
First Author: Tarik Salman
- BOARD F21:** Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy. (Abstract 616)
First Author: Thomas John Semrad

- BOARD F22:** Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab). (Abstract 617)
First Author: Dominik Paul Modest
- BOARD G1:** Relations of T-cell and B-cell area ratios and the number of natural killer cells (NK cells) in lymph nodes (LNs) to outcomes in patients with stage II colon cancer. (Abstract 618)
First Author: Kazutake Okada
- BOARD G2:** C6-ceramide's effect on KRAS-defined colorectal cancer cells treated with oxaliplatin, 5-fluorouracil with and without cetuximab. (Abstract 619)
First Author: Alvaro G. Menendez
- BOARD G3:** Translational investigations of gastrointestinal malignancies using spheroid cultures. (Abstract 620)
First Author: Evie Carchman
- BOARD G5:** Hypermethylated circulating DNA detection using picoliter droplet-based PCR in colorectal cancer. (Abstract 622)
First Author: Geraldine Perkins
- BOARD G6:** A single institution experience of EGFR inhibitors in patients with advanced squamous cell anal carcinomas (SCAC). (Abstract 623)
First Author: Dae Won Kim
- BOARD G7:** Micro-RNAs as positive biomarkers of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal carcinoma. (Abstract 624)
First Author: Erika B. Ruiz Garcia
- BOARD G8:** Suppressive signals in colorectal cancer: RasGRP1 a new marker for anti-EGFR therapy? (Abstract 625)
First Author: Jeroen Roose
- BOARD G9:** BASAL immunologic response and its modifications after treatment with ANTI-EGFR in patients with advanced colorectal cancer. (Abstract 626)
First Author: Jose M. Vieitez
- BOARD G10:** Association of isocitrate dehydrogenase-1 (IDH-1) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer. (Abstract 627)
First Author: Nazanin Fallah-Rad
- BOARD G11:** Clinical study on medical value of adoptive immunotherapy with chemotherapy for stage IV colorectal cancer (COMVI study). (Abstract 628)
First Author: Yoichiro Yoshida

GENERAL POSTER SESSION C, *continued*

- BOARD G12:** Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients. (Abstract 629)
First Author: Akihito Kawazoe
- BOARD G13:** Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer. (Abstract 630)
First Author: Ron Bose
- BOARD G14:** The effect of Wnt9A induced by lithium chloride on β -catenin and colorectal cancer cell proliferation. (Abstract 631)
First Author: Donald Peter Braun
- BOARD G15:** Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab. (Abstract 632)
First Author: Stefano Cascinu
- BOARD G16:** The prospective French participation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients' characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy. (Abstract 633)
First Author: Thierry Andre
- BOARD G17:** TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase 3 RECURSE trial. (Abstract 634)
First Author: Robert J. Mayer
- BOARD G18:** Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: A multicentre randomized phase II trial (NEXIRI 2). (Abstract 635)
First Author: Emmanuelle Samalin
- BOARD G19:** Real-world cancer regimen costs for metastatic colorectal cancer patients treated with biologics in first- through second-line. (Abstract 636)
First Author: Stephen Johnston
- BOARD G20:** SIRFLOX: Differences in site of first progression between mFOLFOX6 \pm bevacizumab (bev) versus mFOLFOX6 \pm bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC). (Abstract 637)
First Author: Peter Gibbs
- BOARD G21:** TAS-102 versus placebo (PBO) in patients (pts) \geq 65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial. (Abstract 638)
First Author: Eric Van Cutsem

- BOARD G22:** Cost-effectiveness analysis of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in patients with isolated hepatic metastases from colorectal cancer (CRC). (Abstract 639)
First Author: Vladimir Kirichenko
- BOARD H1:** Frequency of unplanned surgical intervention in patients with stage IV colorectal cancer receiving palliative chemotherapy: An analysis of SEER-Medicare. (Abstract 640)
First Author: Patrick D. Lorimer
- BOARD H2:** Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials. (Abstract 641)
First Author: Sarah Chrabaszcz
- BOARD H3:** An open label, randomized phase 3 trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC. (Abstract 642)
First Author: Tae Won Kim
- BOARD H4:** TOPO1 expression in primary and metastatic GI cancers. (Abstract 643)
First Author: Michael Castro
- BOARD H5:** Outcomes of patients (pts) with BRAF mutated (BRAF MT) Colorectal Cancer (CRC): The Royal Marsden Experience. (Abstract 644)
First Author: Hamzeh Kayhanian
- BOARD H6:** How are colorectal cancer (CRC) patients treated following cancer recurrence during follow-up? (Abstract 645)
First Author: Katherine Van Loon
- BOARD H7:** Phase III RECURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups. (Abstract 646)
First Author: Atsushi Ohtsu
- BOARD H8:** Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study. (Abstract 647)
First Author: Eric Van Cutsem
- BOARD H9:** Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. (Abstract 648)
First Author: Christopher J. O'Callaghan
- BOARD H10:** Survival determinants with matched targeted therapies in BRAF mutant metastatic colorectal cancer (mCRC). (Abstract 649)
First Author: Enrique Sanz-Garcia

GENERAL POSTER SESSION C, *continued*

- BOARD H11:** Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour. (Abstract 650)
First Author: Belinda Lee
- BOARD H12:** Outcome of patients with KRAS exon 2 wildtype (KRAS-wt) metastatic colorectal carcinoma (mCRC) with cetuximab-based first-line treatment in the noninterventional study ERBITAG and impact of comorbidity and age. (Abstract 651)
First Author: Stephan Sahn
- BOARD H13:** Comparative effectiveness of panitumumab (P) and cetuximab (C) in metastatic colorectal cancer (mCRC) with wild-type KRAS (WTKRAS). (Abstract 652)
First Author: Yifan Xu
- BOARD H14:** Targeted therapy for gastrointestinal (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. (Abstract 653)
First Author: Herbert Hurwitz
- BOARD H15:** Outcomes after noncurative locoregional treatment in patients with unresectable metastatic colorectal carcinoma. (Abstract 654)
First Author: Qiong Yang
- BOARD H16:** Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity. (Abstract 655)
First Author: Wen Wee Ma
- BOARD H17:** Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database. (Abstract 656)
First Author: Jan Franko
- BOARD H18:** Effect of combined neoadjuvant chemoradiation on overall survival for patients with locally advanced rectal cancer. (Abstract 657)
First Author: Zhifei Sun
- BOARD H19:** Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database. (Abstract 658)
First Author: Miriam Koopman
- BOARD H20:** Impact of comorbidities using Adult Comorbidity Evaluation-27 (ACE-27) score on survival in stage II colon cancer: Age, TNM staging, and pathological high risk-disease. (Abstract 659)
First Author: Manik A. Amin
- BOARD H21:** Chasing the proverbial unicorn of relative value units (RVU) and block time. (Abstract 660)
First Author: Rahul Rajeev

- BOARD H22:** Oncologic outcome of lateral pelvic lymph node metastasis in locally advanced rectal cancer. (Abstract 661)
First Author: HyungJin Kim
- BOARD J1:** Stereotactic body radiation therapy for local control of liver metastases from colorectal cancer. (Abstract 662)
First Author: Ji Hyeon Joo
- BOARD J2:** Assessment of treatment with panitumumab, cetuximab, and bevacizumab among mCRC patients with wild-type RAS or BRAF treated at community cancer centers in the United States. (Abstract 663)
First Author: Kimberly Lowe
- BOARD J3:** Resection of non-regional lymph node metastasis in patients with colorectal cancer. (Abstract 664)
First Author: Christina Edwards Bailey
- BOARD J4:** Patterns in KRAS testing and EGFRi therapy across lines of treatment for metastatic colorectal cancer in Canada: A retrospective analysis. (Abstract 665)
First Author: Hagen F. Kennecke
- BOARD J5:** Two-stage hepatectomy for colorectal metastases: Association of a good pathologic response to intensified preoperative chemotherapy with second stage completion and longer survival. (Abstract 666)
First Author: François Quenet
- BOARD J6:** Multiple immunological mechanisms of cancer cachexia in patients with solid tumors. (Abstract 667)
First Author: Kenji Gonda
- BOARD J7:** Loco-regional outcomes of a population-based cohort of rectal neuroendocrine tumors. (Abstract 668)
First Author: Erica S. Tsang
- BOARD J8:** Predictive factor for toxicities and treatment termination in adjuvant S-1 therapy for stage III colorectal cancer using data from JCOG0910. (Abstract 669)
First Author: Kentaro Yamazaki
- BOARD J9:** Effect of vorinostat (VOR) and hydroxychloroquine (HCQ) on immunity and autophagy in metastatic colorectal cancer (mCRC). (Abstract 670)
First Author: Sukeshi R. Patel
- BOARD J10:** ARID1A alterations in gastrointestinal cancers as therapeutic opportunities. (Abstract 671)
First Author: Gargi D. Basu
- BOARD J11:** Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC). (Abstract 672)
First Author: Michael Teufel

GENERAL POSTER SESSION C, *continued*

- BOARD J12:** Induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC): The phase II TRUST trial. (Abstract 673)
First Author: Caterina Vivaldi
- BOARD J13:** Chemotherapy (Ctx) use and adoption of new agents in older versus younger patients (pts) with metastatic colorectal cancer (mCRC). (Abstract 674)
First Author: Namrata Vijayvergia
- BOARD J14:** Impact of prophylactic treatments of cetuximab-based skin reactions in patients with metastatic colorectal carcinoma (mCRC): Interim analysis of the German noninterventional study ERBITAG. (Abstract 675)
First Author: Stephan Sahn
- BOARD J15:** A phase II study of bevacizumab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS mutant-type metastatic colorectal cancer. (Abstract 676)
First Author: Tetsuya Eto
- BOARD J16:** Optimal timing for curative surgery after preoperative chemoradiotherapy in locally advanced rectal cancer. (Abstract 677)
First Author: Yoo-Kang Kwak
- BOARD J17:** Prognostic significance of lymph node sampling in node-negative appendiceal carcinoids. (Abstract 678)
First Author: Mustafa Raouf
- BOARD J18:** A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer. (Abstract 679)
First Author: May Thet Cho
- BOARD J19:** Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS). (Abstract 680)
First Author: Yoshito Komatsu
- BOARD J20:** Quality of life (QoL) and therapy management in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): Interim results of the noninterventional QoLiTrap-study. (Abstract 681)
First Author: Ralf Hofheinz
- BOARD K1:** The relationship between systemic inflammation and postoperative outcomes following neoadjuvant chemoradiotherapy for rectal cancer. (Abstract 682)
First Author: Stephen Thomas McSorley
- BOARD K2:** Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients. (Abstract 683)
First Author: Wen-zhuo He

- BOARD K3:** Clinicopathologic characteristics that affect the treatment and recurrence of rectal carcinoid tumor in Korea. (Abstract 684)
First Author: Dong Ho Lee
- BOARD K4:** Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC). (Abstract 685)
First Author: Matthew E. Burge
- BOARD K5:** Clinical effectiveness of adjuvant chemotherapy (AC) with or without oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) in stage II rectal cancer (RC). (Abstract 686)
First Author: Jonathan M. Loree
- BOARD K6:** X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC). (Abstract 687)
First Author: John H. Strickler
- BOARD K7:** Innovation or disparity? National trends in nonoperative management of rectal adenocarcinoma. (Abstract 688)
First Author: Clayton Tyler Ellis
- BOARD K8:** Activity of aflibercept (Afli) in combination with FOLFIRI (F) for patients with metastatic colorectal cancer (mCRC) in a real-life setting in Spain: Final results of the retrospective study Named Patient Program. (Abstract 689)
First Author: Javier Sastre
- BOARD K9:** A national survey on the management of liver metastases from colorectal cancer (CRC): Comparison of perspectives and expectations among medical oncologists and hepatobiliary surgeons across Canada. (Abstract 690)
First Author: Maria Yi Ho
- BOARD K10:** Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base (NCDB). (Abstract 691)
First Author: Helmneh M. Sineshaw
- BOARD K11:** The impact of preoperative dexamethasone on the postoperative systemic inflammatory response and complications following surgery for colorectal cancer. (Abstract 692)
First Author: Stephen Thomas McSorley
- BOARD K12:** Which is the better prognostic factor in rectal cancer patients who received neoadjuvant chemoradiotherapy: cTNM stage vs. ypTNM stage? (Abstract 693)
First Author: HyungJin Kim
- BOARD K13:** Colorectal liver metastases management in the Veterans Health Administration: Geographic disparity. (Abstract 694)
First Author: Dalia A. Mobarek

GENERAL POSTER SESSION C, *continued*

- BOARD K14:** Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States. (Abstract 695)
First Author: Kimberly Lowe
- BOARD K15:** Evaluation of an interactive electronic patient-reported outcome (e-PRO) system in outpatient with oral chemotherapy. (Abstract 696)
First Author: Marika Anna Rasschaert
- BOARD K16:** Longitudinal follow-up of quality of life in gastrointestinal cancer patients after curative surgery in South Korea. (Abstract 697)
First Author: Dae Young Zang
- BOARD K17:** Use and impact of bevacizumab in patients undergoing liver resection for metastatic colorectal cancer in routine clinical practice. (Abstract 698)
First Author: Edmond Michael Kwan
- BOARD K18:** Treatment patterns and outcomes in metastatic colorectal cancer (mCRC). (Abstract 699)
First Author: Thomas H. Cartwright
- BOARD K19:** Phase II trial of induction mFOLFOX6 plus bevacizumab followed by neoadjuvant S-1-based chemoradiation for MRI-defined poor-risk rectal cancer. (Abstract 700)
First Author: Tsuyoshi Konishi
- BOARD K20:** Efficacy and safety of FOLFIRI regimen in elderly versus nonelderly patients with advanced colorectal and gastric cancer. (Abstract 701)
First Author: Jin Won Kim
- BOARD K21:** Utilization and effectiveness of adjuvant chemotherapy (ACT) for colon cancer (CC) in the general population. (Abstract 702)
First Author: James Joseph Biagi
- BOARD K22:** Randomized phase II trial of prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in CapeOX for stage II/III colon cancer patients (YCOG1205). (Abstract 703)
First Author: Jun Watanabe
- BOARD L1:** A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC0808): Final analysis for survival. (Abstract 704)
First Author: Hiroshi Tamagawa
- BOARD L2:** Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy in unfit or older metastatic colorectal cancer patients: A systematic review and pooled-analysis. (Abstract 705)
First Author: Lorenzo Antonuzzo

- BOARD L3:** Personalized dose monitoring of fluorouracil and metabolites of capecitabine (XELODA) in colorectal cancer patients (PersonaX). (Abstract 706)
First Author: Masato Nakamura
- BOARD L4:** The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal carcinomatosis (PC) of appendiceal origin (AO). (Abstract 707)
First Author: Armando Sardi
- BOARD L5:** Does the dose of leucovorin (LV) matter with 5-fluorouracil (5FU) in colorectal cancer (CRC)? (Abstract 708)
First Author: James Joseph Biagi
- BOARD L6:** Evaluation of hypersensitivity reactions to oxaliplatin in gastrointestinal malignancies. (Abstract 709)
First Author: Kelly Markey
- BOARD L7:** Leptomeningeal carcinomatosis in colorectal cancer: The Mayo Clinic experience. (Abstract 710)
First Author: Gretchen E. Taylor
- BOARD L8:** Adjuvant pelvic radiotherapy in patients with stage IVA rectal adenocarcinoma. (Abstract 711)
First Author: Croix C. Fossum
- BOARD L9:** Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine-based regimens: A retrospective tertiary care centre experience. (Abstract 712)
First Author: Arvind Sahu
- BOARD L10:** Pathologic complete response rates after neoadjuvant treatment in rectal cancer: An analysis of the NCDB. (Abstract 713)
First Author: Patrick D. Lorimer
- BOARD L11:** Race-based socioeconomic and treatment disparities in adolescent and young adults with stage II-III rectal cancer. (Abstract 714)
First Author: David Y. Lee
- BOARD L12:** The usefulness of clinical pathways (CP) in managing quality and cost in oncology networks. (Abstract 715)
First Author: Peter G. Ellis
- BOARD L13:** Nomogram including pretherapeutic parameters for prediction of early response after neoadjuvant treatment in rectal cancer: Results from a prospective randomized study. (Abstract 716)
First Author: Jianwei Zhang
- BOARD L14:** Predictors of lymph node metastasis and prognosis in early colorectal cancer patients with signet-ring cell and mucinous adenocarcinomas. (Abstract 717)
First Author: Baorong Song

GENERAL POSTER SESSION C, *continued*

- BOARD L15:** Effects of adjuvant oxaliplatin on anal function in locally advanced rectal cancer treated with preoperative chemoradiotherapy and low anterior resection. (Abstract 718)
First Author: Fernando Arias
- BOARD L16:** Preliminary safety and efficacy of perioperative COI-B (capecitabine, oxaliplatin, irinotecan, and bevacizumab) in patients with borderline resectable or high-recurrence risk colorectal cancer liver metastases (CLM). (Abstract 719)
First Author: Marta Caporale
- BOARD L17:** Short- and long-term outcomes of neoadjuvant-synchronous S-1+radiotherapy for locally advanced rectal cancer: Multicenter phase II study. (Abstract 720)
First Author: Takahiro Hiratsuka
- BOARD L18:** Prognostic significance of regional lymph nodes status in stage IV colorectal cancer. (Abstract 721)
First Author: Shahid Ahmed
- BOARD L19:** Capecitabine dosing using skeletal muscle index (SMI) compared to body surface area (BSA). (Abstract 722)
First Author: Julia Sun
- BOARD L20:** A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer. (Abstract 723)
First Author: Toshiki Masuishi
- BOARD L21:** Time to first-line chemotherapy and travel distance to the cancer center and their relationship to subsequent-line therapies in stage IV CRC. (Abstract 724)
First Author: Mahjabeen Iqbal
- BOARD L22:** Safety and feasibility of laparoscopic surgery for colorectal cancer in elderly patients (YSURG1401 study). (Abstract 725)
First Author: Yosuke Atsumi
- BOARD M1:** Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: Final overall survival analysis of phase II study. (Abstract 726)
First Author: Lucjan Wyrwicz
- BOARD M2:** A pilot study of neoadjuvant chemoradiotherapy for unresectable locally advanced adherent colon cancer: Assessing local tumor response. (Abstract 727)
First Author: Xin Yu
- BOARD M3:** Systemic therapy for advanced anorectal squamous cell carcinomas: A single institutional experience. (Abstract 728)
First Author: Patrick McKay Boland

- BOARD M4:** Colorectal cancer patient outcomes in Nigeria: Results from the African Colorectal Cancer Group. (Abstract 729)
First Author: Olusegun Isaac Alatise
- BOARD M5:** A multicenter phase II study on the feasibility and efficacy of neoadjuvant chemotherapy for locally advanced rectal cancer. (Abstract 730)
First Author: Saori Goto
- BOARD M6:** Systemic therapy in anorectal melanomas: Does choice of systemic therapy matter? (Abstract 731)
First Author: Nitin Kumar Singhal
- BOARD M7:** Perioperative outcomes for robotic total mesorectal excision after preoperative chemoradiation for rectal cancer. (Abstract 732)
First Author: Ibrahim Nassour
- BOARD M8:** Metastatic colorectal cancer (mCRC) treatment: A high-volume, single-center, real-life experience. (Abstract 733)
First Author: Francesca Bergamo
- BOARD M9:** Factors associated with acute toxicity during chemoradiation therapy for rectal cancer. (Abstract 734)
First Author: Pooja Monpara
- BOARD M10:** Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study. (Abstract 735)
First Author: Udit Verma
- BOARD M11:** Weekly bolus 5-fluorouracil and bevacizumab in the palliative treatment of metastatic colorectal cancer. (Abstract 736)
First Author: Michelle Jane Cook
- BOARD M12:** Rectal adenocarcinoma: Surveillance and timing of surgical resection after neoadjuvant chemoradiotherapy in a retrospective cohort. (Abstract 737)
First Author: Vanessa Pachón Olmos
- BOARD M13:** Metastatic lymph node ratio as an independent prognostic factor in stage III gastric cancer after D2 nodal dissection. (Abstract 738)
First Author: Jieer Ying
- BOARD M14:** Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for stage III colon cancer patients who underwent curative resection (KSCC1303). (Abstract 739)
First Author: Nobutomo Miyanari
- BOARD M15:** Blood serum albumin as prognostic factor in patients with colorectal carcinoma. (Abstract 740)
First Author: Luis F. Onate-Ocana

GENERAL POSTER SESSION C, *continued*

- BOARD M16:** Treatment strategy for obstructive colorectal cancer. (Abstract 741)
First Author: Shiro Iwagami
- BOARD M17:** Use and impact of selective internal radiation therapy (SIRT) in routine care patients with metastatic colorectal cancer (mCRC). (Abstract 742)
First Author: Belinda Lee
- BOARD M18:** Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the GERCOR index. (Abstract 743)
First Author: Osamu Muto
- BOARD M19:** Treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC): Continuation of anti-EGFR therapy while switching chemotherapy regimen. (Abstract 744)
First Author: Liubov Yu Vladimirova
- BOARD M20:** Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors. (Abstract 745)
First Author: Hui-Jen Tsai
- BOARD M21:** Phase II study of the early start of chemotherapy after excision of primary colorectal cancer with distant metastases (Pearl Star 02). (Abstract 746)
First Author: Syu Tanimura
- BOARD M22:** Outcome comparison between bridge to surgery stenting and emergency surgery in stage II, III obstructive left colon cancer: A multicenter retrospective study. (Abstract 747)
First Author: Han-mo Yoo
- BOARD N1:** Effect of first-line molecular targeted agents on the efficacy of second-line bevacizumab-containing regimen for metastatic colorectal cancer. (Abstract 748)
First Author: Hiroko Hasegawa
- BOARD N2:** Phase II study of irinotecan and bevacizumab plus alternate day S-1 as second-line treatment in patients with metastatic colorectal cancer. (Abstract 749)
First Author: Chihiro Tanaka
- BOARD N3:** Effects of adjuvant 5FU/oxaliplatin chemotherapy in individuals treated for colon cancer on cognitive and mobility function. (Abstract 750)
First Author: Howard John Lim
- BOARD N4:** An open-label, randomized, parallel-group study of the pharmacokinetics of trifluridine as a component of TAS-102 versus FTD alone. (Abstract 751)
First Author: Weijing Sun
- BOARD N5:** Impact of relative dose intensity and G-CSF use in the adjuvant treatment of resected colon cancer. (Abstract 752)
First Author: Daniel Adam Breadner

- BOARD N6:** Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802—Analysis of early tumor shrinkage (ETS). (Abstract 753)
First Author: Satoshi Yuki
- BOARD N7:** “Real world” effectiveness of different postoperative adjuvant chemotherapy regimens in stage III colon cancer patients. (Abstract 754)
First Author: Jy Ming Chiang
- BOARD N8:** Pre-treatment serum folate levels and toxicity in colorectal cancer patients treated with 5-fluorouracil and folinic acid. (Abstract 755)
First Author: Michael Yan
- BOARD N9:** Risk evaluation of postoperative complication in patients undergoing rectal cancer surgery. (Abstract 756)
First Author: Hiroshi Miyakita
- BOARD N10:** Outcomes after resection of pulmonary metastases in patients with colorectal cancer. (Abstract 757)
First Author: Kaihong Mi
- BOARD N12:** A phase I study of combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab. (Abstract 759)
First Author: Naoki Takahashi
- BOARD N13:** Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after neoadjuvant chemoradiation therapy. (Abstract 760)
First Author: Chang-gon Kim
- BOARD N14:** Review of efficacy and safety of the new oral anticoagulants (NOACS) in the treatment of venous thromboembolism in gastrointestinal (GI) oncology patients. (Abstract 761)
First Author: Hitendra Patel
- BOARD N15:** Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases. (Abstract 762)
First Author: Louise Catherine Connell
- BOARD N16:** Effect of regorafenib and TAS-102 in metastatic colorectal cancer (mCRC) patients on survival in salvage line with different toxicity profile. (Abstract 763)
First Author: Naotoshi Sugimoto
- BOARD N17:** REOX: Effectiveness evaluation of re-exposure to oxaliplatin in patients with metastatic colorectal cancer. (Abstract 764)
First Author: Talita Gonzaga Costa

GENERAL POSTER SESSION C, *continued*

- BOARD N18:** The effect of body mass index (BMI) and nutrition on morbidity and mortality in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). (Abstract 765)
First Author: Komal Patel
- BOARD N19:** Intravenous weekly high-dose infusion of 5-fluorouracil and folinic acid in previously heavily pretreated patients with metastatic colorectal cancer. (Abstract 766)
First Author: Gudrun Piringner
- BOARD N20:** Impact of blue 465nm LED on suppression of cancer growth. (Abstract 767)
First Author: Kozo Yoshikawa
- BOARD N21:** The cancer vaccine therapy using DCs derived from iPS cells (iPSCs) expressing TAA gene. (Abstract 768)
First Author: Hiromitsu Iwamoto
- BOARD N22:** Metastasectomy or radiofrequency ablation for treatment for colorectal cancer liver metastasis: Comparison of recurrence rates and identification of risk factors for local recurrence. (Abstract 769)
First Author: Naik Vietti-Violi
- BOARD O1:** A single institute retrospective trial of concurrent chemotherapy with SIR-Sphere versus SIR-Sphere alone in patients with chemotherapy-resistant colorectal cancer liver metastases. (Abstract 770)
First Author: May Thet Cho
- BOARD O2:** Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902—Comparison of administration interval in cetuximab treatment. (Abstract 771)
First Author: Tomohiro Kondo

7:00 AM–7:55 AM and 12:30 PM–2:00 PM

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

LEVEL 1, WEST HALL

Posters by Topic

Translational Research: *Poster Boards 03–06*

Multidisciplinary Treatment: *07–021*

- BOARD 03:** Phase II study for determining usefulness of FDG-PET as imaging biomarker in regorafenib treatment for metastatic colorectal cancer (JACCRO CC-12). (Abstract TPS772)
First Author: Masato Nakamura
- BOARD 04:** Regorafenib in metastatic colorectal cancer: An exploratory biomarker trial. (Abstract TPS773)
First Author: Mohamed E. Salem
- BOARD 05:** HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial. (Abstract TPS774)
First Author: Salvatore Siena
- BOARD 06:** Statistical analysis of episensitization using transition probability functions and PFS2 for “ROCKET”, a two stage phase II study of RRx-001, a multi-epigenetic agent, investigating resensitization to irinotecan in colorectal cancer. (Abstract TPS775)
First Author: Nacer Abrouk
- BOARD 07:** PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (Abstract TPS776)
First Author: Takayuki Yoshino
- BOARD 08:** The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases. (Abstract TPS777)
First Author: Yasunori Emi
- BOARD 09:** RX-5902: A phosphorylated p68 targeting agent to treat subjects with advanced solid tumors. (Abstract TPS778)
First Author: Martin Gutierrez
- BOARD 010:** A randomized, phase II study of high-risk colorectal cancer patients (Stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX. (Abstract TPS779)
First Author: Thomas H. Cartwright

TRIALS IN PROGRESS POSTER SESSION C, *continued*

- BOARD O11:** A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT). (Abstract TPS780)
First Author: Kei Muro
- BOARD O12:** Capecitabine maintenance therapy after adjuvant chemotherapy of FOLFOX (or XELOX) in patients with stage IIIC or R0 resected stage IV colorectal cancer (CAMCO study). (Abstract TPS781)
First Author: Jiayu Ling
- BOARD O13:** The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer—A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). (Abstract TPS782)
First Author: Johannes H.W. de Wilt
- BOARD O14:** Neoadjuvant chemotherapy alone with mFOLFOXIRI in locally advanced rectal cancer: A single-arm phase II study. (Abstract TPS783)
First Author: Yanhong Deng
- BOARD O15:** Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer. (Abstract TPS784)
First Author: Sanjay Goel
- BOARD O16:** Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study. (Abstract TPS785)
First Author: David Cunningham
- BOARD O17:** Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal. (Abstract TPS786)
First Author: Marwan Fakih
- BOARD O18:** KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma. (Abstract TPS787)
First Author: Dung T. Le
- BOARD O19:** The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC). (Abstract TPS788)
First Author: Elske C. Gootjes

BOARD O20: KEYNOTE-177: First-line, open-label, randomized, phase 3 study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma. (Abstract TPS789)
First Author: Luis A. Diaz

BOARD O21: Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: The CHARISMA randomized multicenter clinical trial. (Abstract TPS790)
First Author: Eric P. Van der Stok

2016 Gastrointestinal Cancers Symposium Supporters*

We gratefully acknowledge the following organizations for their support of the Symposium:

PLATINUM SUPPORTER

Lilly

BRONZE SUPPORTERS

Celgene Corporation
Incyte Corporation
Ipsen Biopharmaceuticals Inc.
Merck & Co., Inc.
Merrimack Pharmaceuticals

GENERAL SUPPORTERS

Ethicon
Pfizer Oncology

MERIT AWARD SUPPORTERS

Amgen
AstraZeneca
Celgene Corporation
Gilead Sciences, Inc.
Janssen Biotech, Inc.
Lilly
Spectrum Pharmaceuticals
Takeda Oncology

PATIENT ADVOCATE SCHOLARSHIP PROGRAM BUNDLE

Amgen
Bristol-Myers Squibb
Celgene Corporation
Conquer Cancer Foundation
Genentech BioOncology™
Lilly
Teva Oncology

GASTROINTESTINAL CANCERS SYMPOSIUM ONSITE CONNECTIVITY RESOURCES BUNDLE

Merrimack Pharmaceuticals

*This list reflects commitments as of December 8, 2015.

Support for this program is funded through

**CONQUER
CANCER**
FOUNDATION
of the American Society of Clinical Oncology